4,687 Matching Annotations
  1. Oct 2026
    1. Ten patients received concomitant immunomodulation (detailed in Supplementary Table S4); six were genotype-predicted as CRIM-negative, three were CRIM-positive, and one lacked genotype data.

      Patient 3

      Variant1: NM_000152.3:c.2481+102_2646+31del

      CAID: CA658795291, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.2481%2B102_2646%2B31del

      gnomAD: n/a

      Variant2: NM_000152.4(GAA):c.307T>G (p.Cys103Gly)

      ClinVar: 92483, https://www.ncbi.nlm.nih.gov/clinvar/variation/92483/

      gnomAD: n/a

    1. 10

      Case#: Subject number 10(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 617 U/L (60-305 U/L is normal), Hex4: 6.6 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal)

      glucosidase activity: GAA activity #1 was 0.84 micromole/L/h and GAA activity #2 (NBS) 0.49 in dried blood spots (>2.10 micromole/L/h is normal). 2.1 in confirmatory testing (>3.88 is normal).

      Variant 1: NM_000152.5(GAA):c.1438-1G>C

      Variant 1 ClinVarID: 189184

      Variant 1 CAid: CA274472

      Variant 2: NM_000152.5(GAA):c.-32-13T>G

      Variant 2 ClinVarID: 4027

      Variant 2 CAid: CA116606

      Zygosity: compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. 30

      Case#: Subject number 30(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      glucosidase activity: GAA activity #2 (NBS) 1.07 in dried blood spots (>2.10 micromole/L/h is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.-32-13T>G

      Variant 2 ClinVarID: 4027

      Variant 2 CAid: CA116606

      Zygosity: homozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    3. 12

      Case#: Subject number 12(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 464 U/L (60-305 U/L is normal)

      glucosidase activity: 2.60 in confirmatory testing (>3.88 is normal). AST: 112 (22–71); ALT: 50 (7–50)

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.2238G>C

      Variant 2 ClinVarID: 265160

      Variant 2 CAid: CA8815665

      Zygosity: compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    4. 3

      Case#: Subject number 3(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 125 U/L (28-300 U/L is normal), AST: 56 U/L (24-72 U/L is normal), ALT: 49 U/L (17-63 U/L is normal), Hex4: 4.5 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal)

      glucosidase activity: GAA activity #1 was 1.73 micromole/L/h and GAA activity #2 (NBS) 1.08 in dried blood spots (>2.10 micromole/L/h is normal). 3.6 in confirmatory testing (>6.7 is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.-32-13T>G

      Variant 2 ClinVarID: 4027

      Variant 2 CAid: CA116606

      Zygosity: homozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    5. 16

      Case#: Subject number 16(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 140 U/L (60-305 U/L is normal), AST: 73 U/L (22-71 U/L is normal), ALT: 39 U/L (7-50 U/L is normal), Hex4: 8.5 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal), BNP 99.8 pg/mL (0.0–100.0 pg/mL is normal)

      glucosidase activity: GAA activity #1 was 1.06 micromole/L/h and GAA activity #2 (NBS) 0.26 in dried blood spots (>2.10 micromole/L/h is normal). 6.4 in confirmatory testing (>3.88 is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.-32-13T>G

      Variant 2 ClinVarID: 4027

      Variant 2 CAid: CA116606

      Zygosity: homozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    6. 8

      Case#: Subject number 8(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 365 U/L (60-305 U/L is normal), Hex4: 5.23 mmol/mol Creatinine (≤8.9 mmol/mol Creatinine is normal)

      glucosidase activity: GAA activity #1 was 0.83 micromole/L/h and GAA activity #2 (NBS) 0.85 in dried blood spots (>2.10 micromole/L/h is normal). 0.93 in confirmatory testing (>3.88 is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.1655 T>C

      Variant 2 ClinVarID: 279811

      Variant 2 CAid: CA8815429

      Zygosity: compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    7. 1

      Case#: Subject number 1(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 530 U/L (28-300 U/L is normal), AST: 72 U/L (24-72 U/L is normal), ALT: 41 U/L (17-63 U/L is normal), Hex4: 4.9 mmol/mol Creatinine (≤20 mmol/mol Creatinine is normal)

      glucosidase activity: GAA activity #1 was 1.86 micromole/L/h and GAA activity #2 (NBS) 0.78 in dried blood spots (>2.10 micromole/L/h is normal). 3.1 in confirmatory testing (>6.7 is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.-32-13T>G

      Variant 2 ClinVarID: 4027

      Variant 2 CAid: CA116606

      Zygosity: homozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. PATIENT 1

      Case#: Patient 1, woman, 58 years old, ethnicity unknown

      DiseaseAssertion:Pompe disease

      Was also misdiagnosed with adult-onset spinal muscular atrophy (SMA)

      FamilyInfo: No family history of muscle disease

      CasePresentingHPOs: HP:0003701, HP:0100284

      (Proximal muscle weakness, EMG myotonic discharges)

      CaseHPOFreeText: Denervation atrophy from a muscle biopsy

      Weakness of hip flexion 2–3/5, hip abduction 2/5, and hip adduction 2/5

      Myotonic discharges were in the lumbar paraspinals, vastus medialis, and tensor fasciae latae muscles.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: GAA enzyme activity assay was 1 pmol/punch/h (normal range 10–49 pmol/punch/h)

      Her creatine kinase (CK) level at presentation had been elevated as high as 429 U/L (normal range 45–145)

      Found with two mutations in the GAA gene

      Variant: NM_000152.5(GAA):c.-32-13T>G

      ClinVar: 4027

      CAID: CA116606

      gnomAD: Highest population MAF= 0.005541 (Ashkenazi Jewish)

      Variant: NM_000152.5(GAA):c.525del (p.Glu176fs) Double check this variant

      ClinVar: 4033

      CAID: CA220406

      gnomAD: N/A

      ParentalGenotype:N/A

      Previously Published: N/A

    1. 3

      Case#: Subject number 3, male, 56 years (report), 30s years (onset), 48 years (diagnosis)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A ** CasePresentingHPOs**: HP:0000365 (hearing loss), HP:0000360 (tinnitus)

      CaseHPOFreeText: ambulatory

      CaseNotHPOs: HP:0002617, HP:0000939, HP:0009830, HP:0100647, HP:0010788, HP:0000821, HP:0002650, HP:0001638 (aneurysm, osteoporosis, peripheral neuropathy, Graves disease, Testicular cancer, hypothyroidism, scoliosis, cardiomyopathy)

      CaseNotHPOFreeText: No infusion reaction, no tracheostomy, not on BiPAP

      CasePreviousTesting: “documented deficiency of acid alpha-glucosidase enzyme activity”; on enzyme replacement therapy

      Variant 1: NM_000152.5(GAA):c.-32-13T>G (p.Tyr766Ser)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.2431delC (p.Leu811TrpfsTer?)

      Variant 2 ClinVarID: N/A

      Variant 2 CAid: CA628018649

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. 16

      Case#: Subject number 16, male, 64 years (report), 56 years (onset), 60 years (diagnosis)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: on BiPAP, ambulatory, assistive device (cane)

      CaseNotHPOs: HP:0009830, HP:0000360, HP:0002650, HP:0000939, HP:0000821, HP:0000365, HP:0002617, HP:0100647, HP:0010788, HP:0001638 (peripheral neuropathy, tinnitus, scoliosis, osteoporosis, hypothyroidism, hearing loss, aneurysm, Graves disease, Testicular cancer, cardiomyopathy)

      CaseNotHPOFreeText: no infusion reaction, no tracheostomy

      CasePreviousTesting: “documented deficiency of acid alpha-glucosidase enzyme activity”; on enzyme replacement therapy

      Variant 1: NM_000152.5(GAA):c.-32-13T>G (p.Tyr766Ser)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.307T>G

      Variant 2 ClinVarID: 92483

      Variant 2 CAid: CA220404

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

    3. 8

      Case#: Subject number 8, female, 49 years (report), 20s years (onset), 42 years (diagnosis)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0000821 (hypothyroidism)

      CaseHPOFreeText: ambulatory, assistive device (quad cane, wheelchair)

      CaseNotHPOs: HP:0000365, HP:0002650, HP:0000360, HP:0002617, HP:0000939, HP:0009830, HP:0100647, HP:0010788, HP:0001638 (hearing loss, scoliosis, tinnitus, aneurysm, osteoporosis, peripheral neuropathy, Graves disease, Testicular cancer, cardiomyopathy)

      CaseNotHPOFreeText: No infusion reaction, no tracheostomy, not on BiPAP

      CasePreviousTesting: “documented deficiency of acid alpha-glucosidase enzyme activity”; on enzyme replacement therapy

      Variant 1: NM_000152.5(GAA):c.-32-13T>G (p.Tyr766Ser)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.1437+2T>C

      Variant 2 ClinVarID: 849313

      Variant 2 CAid: CA401366685

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    4. 5

      Case#: Subject number 5, male, 59 years (report), 10 years (onset), 33 years (diagnosis)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0000365 (hearing loss), HP:0000360 (tinnitus), HP:0000939 (osteoporosis)

      CaseHPOFreeText: Tracheostomy, assistive device (wheelchair)

      CaseNotHPOs: HP:0002650, HP:0002617, HP:0009830, HP:0100647, HP:0010788, HP:0000821, HP:0001638 (scoliosis, aneurysm, peripheral neuropathy, Graves disease, Testicular cancer, hypothyroidism, cardiomyopathy)

      CaseNotHPOFreeText: No infusion reaction, no ambulatory, not on BiPAP

      CasePreviousTesting: “documented deficiency of acid alpha-glucosidase enzyme activity”; on enzyme replacement therapy

      Variant 1: NM_000152.5(GAA):c.-32-13T>G (p.Tyr766Ser)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.925G>A (p.Gly309Arg)

      Variant 2 ClinVarID: 188797

      Variant 2 CAid: CA273972

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    5. 15

      Case#: Subject number 15, male, 42 years (report), 15 years (onset), 23 years (diagnosis)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: on BiPAP, ambulatory

      CaseNotHPOs: HP:0009830, HP:0000360, HP:0002650, HP:0000939, HP:0000821, HP:0000365, HP:0002617, HP:0100647, HP:0010788, HP:0001638 (peripheral neuropathy, tinnitus, scoliosis, osteoporosis, hypothyroidism, hearing loss, aneurysm, Graves disease, Testicular cancer, cardiomyopathy)

      CaseNotHPOFreeText: no infusion reaction, no tracheostomy

      CasePreviousTesting: “documented deficiency of acid alpha-glucosidase enzyme activity”; on enzyme replacement therapy

      Variant 1: NM_000152.5(GAA):c.-32-13T>G (p.Tyr766Ser)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.1134C>G

      Variant 2 ClinVarID: 595469

      Variant 2 CAid: CA401365023

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    6. 9

      Case#: Subject number 9, female, 74 years (report), 30s years (onset), 62 years (diagnosis)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0000365 (hearing loss), HP:0000360 (tinnitus)

      CaseHPOFreeText: Infusion reaction, ambulatory, assistive device (cane for long distance)

      CaseNotHPOs: HP:0000821, HP:0002650, HP:0002617, HP:0000939, HP:0009830, HP:0100647, HP:0010788, HP:0001638 (hypothyroidism, scoliosis, aneurysm, osteoporosis, peripheral neuropathy, Graves disease, Testicular cancer, cardiomyopathy)

      CaseNotHPOFreeText: no tracheostomy, not on BiPAP

      CasePreviousTesting: “documented deficiency of acid alpha-glucosidase enzyme activity”; on enzyme replacement therapy

      Variant 1: NM_000152.5(GAA):c.-32-13T>G (p.Tyr766Ser)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.2655_2656delCG (p.Val886GlufsTer2)

      Variant 2 ClinVarID: 597005

      Variant 2 CAid: CA913191011

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. 24/F

      Patient24: Female

      CasePresentingHPOs: HP:0000365

      HPOsFreeText: CRIM positive, heart normalization

      CaseNotHPOs: HP:0004887, HP:0025156, HP:0002355, HP:0002546, HP:0001371

      NotHPOsFreeText: infusion associated reaction

      CaseAddInfo: variants in trans, symptom onset at 2yo, diagnosis at 3yo, ERT at 4yo

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.1933G>A (p.Asp645Asn)

      ClinVar: 188728, https://www.ncbi.nlm.nih.gov/clinvar/variation/188728/

      gnomAD: 0.000008250, http://gnomad.broadinstitute.org/variant/17-78086719-G-A

      Variant2: NM_000152.3:c.1822C>T

      CAID: CA8815488, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1822C%3ET

      gnomAD: 0.00001806, http://gnomad.broadinstitute.org/variant/17-78086444-C-T

    2. 27/M

      Patient27: Male

      CasePresentingHPOs: HP:0000365

      HPOsFreeText: CRIM positive, Anti-rh GGA antibodies maximum titer = ≤ 1:400, moderate periventricular white matter abnormalities (hypomyelination), progressive deterioration of MRI parameters

      CaseNotHPOs: HP:0004887, HP:0025156, HP:0002355, HP:0002546, HP:0001371

      NotHPOsFreeText: infusion associated reaction, heart normalization

      CaseAddInfo: variants in trans, symptom onset at birth, diagnosis at 3yo, ERT at 4yo

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.1465G>A (p.Asp489Asn)

      ClinVar: 92465, https://www.ncbi.nlm.nih.gov/clinvar/variation/92465/

      gnomAD: 0.00001195, http://gnomad.broadinstitute.org/variant/17-78084553-G-A

      Variant2: NM_000152.3:c.40_47del

      CAID: CA913184761, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA913184761

      gnomAD: n/a

    1. 4

      Patient4: Female

      CasePresentingHPOs: HP:0004887, HP:0002194, HP:0001522

      HPOsFreeText: ERT dosage = 20 mg/kg/2 w, able to hold objects, CRIM negative

      CaseNotHPOs:

      NotHPOsFreeText: no reversal of HCM

      CaseAddInfo: Symptom onset and diagnosis at 2mo, ERT at 3.5mo, ERT lasted for 8mo, ventilation required at 11mo, died at 12mo

      CasePMIDs: 22252923, 27629047

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.1657C>T

      CAID: CA401368835, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1657C%3ET

      gnomAD: n/a

    2. 18

      Patient18: Male

      CasePresentingHPOs: HP:0004887, HP:0003819

      HPOsFreeText: ERT dosage = 20mg/kg/2w, able to hold objects, CRIM negative

      CaseNotHPOs:

      NotHPOsFreeText: No HCM reversal

      CaseAddInfo: Symptom onset at 6mo, diagnosis and ERT at 12mo, ERT lasted for 9mo, required ventilation at 34mo, died at 42mo

      CasePMIDs: 22252923, 27629047

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.1657C>T

      CAID: CA401368835, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1657C%3ET

      gnomAD: n/a

    1. 7

      Case7: Male, Danish, 20 years report, 1 year onset

      HPOsFreeText: MRC score is 4/5 (thigh/calf), Forced vital capacity sitting/supine is 5.6/5.3 (L), Has started ERT

      CaseNotHPOs: HP:0008956 (Thigh muscle atrophy)

      GroupGenotypingMethod: Mutation Analysis on the GAA Gene


      Variant1: NM_000152.4:c.2228A>G (p.Gln743Arg)

      CAID: CA401324753 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.2228A%3EG

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.2237G>C (p.Trp746Ser)

      ClinVar: 188484 https://www.ncbi.nlm.nih.gov/clinvar/variation/188484/

      gnomAD: African 3.210e-4, Overall 7.089e-5 http://gnomad.broadinstitute.org/variant/17-78090814-G-C


      Variant3: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      CaseAddInfo: Late Onset Pompe Disease, Nomenclature indicates Variants 1 and 2 are in cis

    2. 4

      Case4: Male, French, 65 years report, 55 years onset

      HPOsFreeText: 6-min walk test achieved 540 m, MRC score is 5/5 (thigh/calf), Forced vital capacity sitting/supine is 2.7/1.8 (L), On the medications Statin and Allopurinol, Has started ERT

      CaseNotHPOs: HP:0008956 (Thigh muscle atrophy)

      GroupGenotypingMethod: Mutation Analysis on the GAA Gene


      Variant1: NM_000152.4:c.-32-13T>A

      CAID: CA913184742 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA913184742

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.3G>A

      CAID: CA401359809 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.3G%3EA

      gnomAD: European (Non-Finnish) 8.945e-6, Overall 4.041e-6 http://gnomad.broadinstitute.org/variant/17-78078388-G-A


      CaseAddInfo: Late Onset Pompe Disease

    1. 8

      Patient8: Female, 41yo at diagnosis, 48yo at ERT

      CasePresentingHPOs:

      HPOsFreeText: anti rh-GAA antibodies titre = 1:1600, enzyme (μmol/g/h) = 0.23 (2-10), mobility aid required before and after ERT

      CaseNotHPOs:

      NotHPOsFreeText: NIV not required

      CaseAddInfo: 7yr disease duration, variants in trans

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.482_483del

      CAID: CA8814879, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA8814879

      gnomAD: 1.729e-05, http://exac.broadinstitute.org/variant/17-78078864-TCC-T

      Variant2: NM_000152.4(GAA):c.692+5G>T

      ClinVar: 562532, https://www.ncbi.nlm.nih.gov/clinvar/variation/526532/

      gnomAD: 8.596e-06, http://exac.broadinstitute.org/variant/17-78079698-G-T

    1. 4

      Case#: Patient 4, male, diagnosed 2015 (not given age of diagnosis), age 42 during study period

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None given

      CaseHPOFreeText: None given

      CaseNotHPOs: None given

      CaseNotHPOFreeText: None given

      CasePreviousTesting: None given

      Variant 1: NM_000152.5:c.-32-13T>A (unclear variant nomenclature)

      Variant 1 ClinVarID: N/A

      Variant 1 CAid: CA913184742

      Variant 2: NM_000152.5:c.525del

      Variant 2 ClinVarID: 4033

      Variant 2 CAid: CA220406

      ParentalGenotype: Not provided

    2. 3

      Case#: Patient 3, female, diagnosed 2015 (not given age of diagnosis), age 40 during study period

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None given

      CaseHPOFreeText: None given

      CaseNotHPOs: None given

      CaseNotHPOFreeText: None given

      CasePreviousTesting: None given

      Variant 1: NM_000152.5:c.-32-13T>G (unclear variant nomenclature, homozygous)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      ParentalGenotype: Not provided

    1. 2

      Case#: Patient 2

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None

      CaseHPOFreeText: None

      CaseNotHPOs: None

      CaseNotHPOFreeText: None

      CasePreviousTesting: Single gene sequencing with Ion Torrent Persional Genome Machine

      Glucosidase activity: 0.0 nmol 5MU/hr/mL

      Variant 1: NM_000152.5:c.596A>G

      Variant 1 ClinVarID: 92486

      Variant 1 CAid: CA145785

      Variant 2: NM_000152.5:c.668G>A

      Variant 2 ClinVarID: 92488

      Variant 2 CAid: CA145791

      ParentalGenotype: Not provided

    2. 3

      Case#: Patient 3

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None

      CaseHPOFreeText: None

      CaseNotHPOs: None

      CaseNotHPOFreeText: None

      CasePreviousTesting: Single gene sequencing with Ion Torrent Persional Genome Machine

      Glucosidase activity: 0.0 nmol 5MU/hr/mL

      Variant 1: NM_000152.5:c.596A>G

      Variant 1 ClinVarID: 92486

      Variant 1 CAid: CA145785

      Variant 2: NM_000152.5:c.668G>A

      Variant 2 ClinVarID: 92488

      Variant 2 CAid: CA145791

      ParentalGenotype: Not provided

    1. 23

      Case#: P 23, Female, 4.7 months old when started ERT (45.8months old when last reported), German

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001639 , HP:0001252 , HP:0003701, HP:0006532, HP:0002650

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Recurrent Pneumonia, Scoliosis)

      CaseHPOFreeText: Scoliosis and recurrent pneumonia were complications during ERT

      No motor activity achieved

      Requiered ventilation and tube feeding

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      Variant: NM_000152.3:c.1456G>C (p.Ala486Pro)

      ClinVar: N/A

      CAID: CA401366835

      gnomAD: N/A

      ParentalGenotype: Both the paternal and maternal allele carried the NM_000152.3:c.1456G>C Variant

      PreviouslyPublished:N/A

    2. 22

      Case#: P 22, Female, 0.2 months old when started ERT (47.0 months old when last reported), German

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001639 , HP:0001252 , HP:0003701, HP:0001371

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Flexion contracture )

      CaseHPOFreeText: Flexion contractures were a complication during ERT

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: No tube feeding nor ventilation needed

      CasePreviousTesting: CRIM status is unknown

      Antibody titer is 1:1.800

      Variant 1: NM_000152.3:c.2004C>A

      ClinVar: N/A

      CAID: CA401370054

      gnomAD: N/A

      Variant: c.541545delTTAC

      ClinVar: N/A

      CAID: N/A

      gnomAD: N/A

      ParentalGenotype: Maternal allele carried the c.2004 C>A Variant

      The paternal allele carried the c.541545delTTAC

      PreviouslyPublished: N/A

    3. 18

      Case#: P 18, Male, 1.4 months old when started ERT (Died at 36.4 months old)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001639 , HP:0001252 , HP:0003701, HP:0006532

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Recurrent Pneumonia)

      CaseHPOFreeText: Recurrent pneumonia was a complication during ERT

      Best motor status was walking

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Did not required ventilation nor tube feeding

      CasePreviousTesting: CRIM status was positive

      Antibody titer was unknown

      Variant: NM_000152.5(GAA):c.896T>C (p.Leu299Pro)

      ClinVar: 180144

      CAID: CA273686

      gnomAD: N/A

      ParentalGenotype: Both the paternal and maternal allele carried the variant NM_000152.5(GAA):c.896T>C (p.Leu299Pro)

      PreviouslyPublished: N/A

    1. #18

      Case#: Subject number 18, female, 79 years (report)

      DiseaseAssertion: Pompe disease

      FamilyInfo: Family member with PD

      CasePresentingHPOs:

      CaseHPOFreeText: Asymptomatic

      CaseNotHPOs: HP:0002153 (hyperkalemia), HP:0001324 (muscle weakness), HP:0003326 (Myalgia), HP:0002015 (dysphagia), HP:0001252 (Hypotonia), HP:0001638 (cardiomyopathy), HP:0002098 (respiratory distress), HP:0003546 (Exercise intolerance), HP:0002094 (dyspnoea)

      CaseNotHPOFreeText: no biopsy

      CasePreviousTesting: "Enzymatic activity was detected by fluorometric techniques" "The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased."

      glucosidase activity: GAA activity was 0.65 mol/Lh in dried blood spots (normal range >0.75).

      Variant 1: NM_000152.5(GAA):c.854C>G (p.Pro285Arg)

      Variant 1 ClinVarID: 225114

      Variant 1 CAid: CA358045

      Variant 2: N/A

      Variant 2 ClinVarID: N/A

      Variant 2 CAid: N/A

      Zygosity: Heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. #6

      Case#: Subject number 6, male, 19 years (report)

      DiseaseAssertion: Pompe disease

      FamilyInfo: Family member with PD

      CasePresentingHPOs:

      CaseHPOFreeText: Asymptomatic

      CaseNotHPOs: HP:0001638 (cardiomyopathy), HP:0002153 (hyperkalemia), HP:0001324 (muscle weakness), HP:0003546 (Exercise intolerance), HP:0001252 (Hypotonia), HP:0003326 (Myalgia), HP:0002015 (dysphagia), HP:0002098 (respiratory distress), HP:0002094 (dyspnoea)

      CaseNotHPOFreeText: no biopsy

      CasePreviousTesting: "Enzymatic activity was detected by fluorometric techniques" "The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased."

      glucosidase activity: GAA activity was 0.37 mol/Lh in dried blood spots (normal range >0.75).

      Variant 1: NM_000152.5(GAA):c.-32-13T>C

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.281_282delCT (p.Pro94ArgfsTer?)

      Variant 2 ClinVarID: 370458

      Variant 2 CAid: CA16041881

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    3. #7

      Case#: Subject number 7, male, 31 years (report)

      DiseaseAssertion: Pompe disease

      FamilyInfo: No known family member with PD

      CasePresentingHPOs: HP:0002153 (hyperkalemia), HP:0001324 (muscle weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0001638 (cardiomyopathy), HP:0003546 (Exercise intolerance), HP:0001252 (Hypotonia), HP:0003326 (Myalgia), HP:0002015 (dysphagia), HP:0002098 (respiratory distress), HP:0002094 (dyspnoea)

      CaseNotHPOFreeText: no biopsy, not asymptomatic

      CasePreviousTesting: "Enzymatic activity was detected by fluorometric techniques" "The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased."

      glucosidase activity: GAA activity was 0.27 mol/Lh in dried blood spots (normal range >0.75).

      Variant 1: NM_000152.5(GAA):c.-32-13T>C

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.1655T>C (p.Leu552Pro)

      Variant 2 ClinVarID: 279811

      Variant 2 CAid: CA8815429

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. c.1327-2A > C

      Case30

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant: NM_000152.4:c.1327-2A>C

      CAID: CA401366173 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1327-2A%3EC

      gnomAD: Not in gnomAD


      CaseAddInfo: Infantile Onset Pompe Disease, Patient is homozygous for this variant

    2. c.148_859-11del(p.Glu50Hisfs*37; exons2–4deletion)

      Case4

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant1: NM_000152.4:c.148_859-11del (p.Glu50Hisfs*37; exons2–4deletion)

      CAID: CA658795223 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.148_859-11del

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.685_686insCGGC (p.Arg229fsProfs*102)

      CAID: CA658795233 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.685_686insCGGC

      gnomAD: Not in gnomAD


      CaseAddInfo: Infantile Onset Pompe Disease

    3. c.1445C > G(p.Pro482Arg)

      Case60

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant1: NM_000152.4:c.1445C>G (p.Pro482Arg)

      CAID: CA401366794 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1445C%3EG

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      CaseAddInfo: Adult Late Onset Pompe Disease, 1 person more with the same genotype

    1. Patient Number 5

      Case5: Female, 11 months report and onset, Algeria, African

      CasePresentingHPOs: HP:0002098, HP:0002883, HP:0000961, HP:0030829, HP:0001290, HP:0003236, HP:0003198, HP:0002878 (Respiratory distress, Rapid breathing, Cyanosis, Abnormal breath sound, Generalized Hypotonia, Increased serum CK, Myopathy, Respiratory failure)

      HPOsFreeText: Intercostal and subcostal retraction, Diffuse infiltrative process involving the left lung field, CK rate was 3 times the normal value and AST and ALT were 2 times the normal value, GAA activity was deficient

      CaseNotHPOs: HP:0030148, HP:0011675, HP:0001315, HP:0001291, HP:0003115 (Heart murmur, Arrhythmia, Decreased/absent deep tendon reflexes, Cranial nerve abnormality, Abnormal ECG)

      CaseAddInfo: Proband was the second born child of healthy consanguineous parents, Pregnancy was uneventful,

    2. Patient Number 6

      Case6: Male, 5 months report, birth onset, Algeria, African

      CasePresentingHPOs: HP:0001635, HP:0001639, HP:0008872, HP:0002015, HP:0000961, HP:0003324, HP:0008936, HP:0000158, HP:0001315, HP:0001263, HP:0000467, HP:0002240, HP:0001640, HP:0002878, HP:0011950, HP:0001270, HP:0001290 (Heart failure, Hypertrophic cardiomyopathy, Feeding difficulties in infancy, Swallowing difficulties, Cyanosis, Generalized weakness, Axial hypotonia, Macroglossia, Decreased/absent deep tendon reflexes, Global developmental delay, Neck muscle weakness, Hepatomegaly, Cardiomegaly, Respiratory failure, Bronchiolitis, Motor delay, Generalized hypotonia)

      HPOsFreeText: Intercostal and subcostal retraction, cardiothoracic ratio of about 0, 78%, CK, ALT, and AST rates were normal, GAA level is null

      CaseAddInfo: Died at 11 months

    1. Case32: Female, 45 years report

      HPOsFreeText: ERT not started, 6 Minute Walking Test at 533 meters, Forced Vital Capacity at 77%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1888+1G>A

      CAID: CA8815511 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1888%2B1G%3EA

      gnomAD: European (Non-Finnish) 9.843e-6, Overall 4.375e-6 http://gnomad.broadinstitute.org/variant/17-78086511-G-A


      CaseAddInfo: Late Onset Pompe Disease

    2. Case9: Female, 34 years report

      HPOsFreeText: 6 years of ERT completed, 6 Minute Walking Test at 452 meters, Forced Vital Capacity at 76%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.1655T>C (p.Leu552Pro)

      ClinVar: 279811 https://www.ncbi.nlm.nih.gov/clinvar/variation/279811/

      gnomAD: European (Non-Finnish) 7.053e-5, Overall 3.188e-5 http://gnomad.broadinstitute.org/variant/17-78085800-T-C


      Variant2: NM_000152.4:c.1688A>T (p.Gln563Leu)

      CAID: CA401368995 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1688A%3ET

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    3. Case19: Male, 57 years report

      HPOsFreeText: 8 years of ERT completed, 6 Minute Walking Test at 273 meters, Forced Vital Capacity at 77%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1819_1836del (p.Gly607_His612del )

      CAID: CA658795266 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1819_1836del

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    1. P1

      PatientF1P1: Female, 30 years onset, 40 years diagnosis, Caucasian

      CasePresentingHPOs: HP:0007340, HP:0002172 (Leg weakness, Postural instability)

      HPOsFreeText: History of hyperCKemia greater than 1,000 U/L (control 30–220 U/L), Showed deficient muscle acid GAA activity (0.05 µmol/min/g, control >0.42 µmol/min/g)

      CaseAddInfo: First cousin twice removed of F1P3, Proband

    1. PD03

      Patient3: Male, northern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.2024A>G

      CAID: CA401370120, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401370120

      gnomAD: n/a

      Variant2: NM_000152.4(GAA):c.2132C>G (p.Thr711Arg)

      ClinVar: 381006, https://www.ncbi.nlm.nih.gov/clinvar/variation/381006/

      gnomAD: 0.0001488, http://exac.broadinstitute.org/variant/17-78087108-C-G

    2. PD22

      Patient22: Female, Southern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.1241del

      CAID: CA913184736, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA913184736

      gnomAD: n/a

      Variant2: NM_000152.4(GAA):c.2662G>T (p.Glu888Ter)

      ClinVar: 578595, https://www.ncbi.nlm.nih.gov/clinvar/variation/578595/

      gnomAD: 1.65e-05, http://exac.broadinstitute.org/variant/17-78092467-G-T

    3. PD12

      Patient12: Male, Southern China

      CasePresentingHPOs:

      HPOsFreeText: IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.2585del

      CAID: CA913184734, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA913184734

      gnomAD: n/a

      Variant2: NM_000152.4(GAA):c.2815_2816delGT (p.Val939Leufs)

      ClinVar: 371481, https://www.ncbi.nlm.nih.gov/clinvar/variation/371481/

      gnomAD: 1.653e-05, http://exac.broadinstitute.org/variant/17-78093082-CTG-C

    1. CaseOPM-2: Male, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 1.34 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.693-5C>T

      CAID: CA8814990 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.693-5C%3ET

      gnomAD: East Asian 3.516e-4, Overall 3.900e-5 http://gnomad.broadinstitute.org/variant/17-78081351-C-T


      Variant2: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      CaseAddInfo: One Pompe Mutation, Nomenclature indicates Variants 1 and 2 are in cis and the other allele is Wildtype

    2. CaseOPOPD-10: Male, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 1.34 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.693-5C>T

      ClinVar: CA8814990 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.693-5C%3ET

      gnomAD: East Asian 3.516e-4, Overall 3.900e-5 http://gnomad.broadinstitute.org/variant/17-78081351-C-T


      Variant2: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      CaseAddInfo: One Pompe Mutation and One Pseudodeficency Mutation

    3. CaseLP2-7: Male, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 0.22 umol/hr/L, Serum CK at 89 U/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.752C>T (p.Ser251Leu)

      ClinVar: 325781 https://www.ncbi.nlm.nih.gov/clinvar/variation/325781/

      gnomAD: East Asian 2.760e-3, Overall 3.540e-4 http://gnomad.broadinstitute.org/variant/17-78081415-C-T


      Variant2: NM_000152.4:c.761C>T (p.Ser254Leu)

      ClinVar: 325782 https://www.ncbi.nlm.nih.gov/clinvar/variation/325782/

      gnomAD: East Asian 2.759e-3, Overall 1.947e-4 http://gnomad.broadinstitute.org/variant/17-78081424-C-T


      Variant3: NM_000152.4:c.1054C>T (p.Gln352Ter)

      CAID: CA294891876 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA294891876

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease, Nomenclature indicates Variants 1 and 2 are in cis

    1. 31

      Case31: Male, 41yo (at enrollment and onset)

      CasePresentingHPOs: HP:0002094, HP:0003701, HP:0003327, HP:0003236, HP:0002098, HP:0002111, HP:0003458, HP:0100284

      HPOsFreeText: asymmetric weakness of extremities, CK = 573 IU/L, required use of ventilator, FVC = 33.7%, unspecific myopathic changes present in muscle pathology, DBS GAA activity = .05, mixed leukocyte GAA activity = 1.40

      CaseNotHPOs: HP:0001627

      NotHPOsFreeText:

      CaseAddInfo:

      CasePreviousTesting: clinical history, laboratory data, DBS and ML assays to measure GAA activity, electromyography, muscle pathology analysis

      CaseGenotypingMethod: full sequencing of GAA gene

      VariantAllele1: NM_000152.3:c.1822C>T

      CAID: CA8815488, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1822C%3ET

      gnomAD: 0.00001806, http://gnomad.broadinstitute.org/variant/17-78086444-C-T

      VariantAllele2: NM_000152.4(GAA):c.2238G>C (p.Trp746Cys)

      ClinVar: 265160, https://www.ncbi.nlm.nih.gov/clinvar/variation/265160/

      gnomAD: 0.0002987, http://exac.broadinstitute.org/variant/17-78090815-G-C

    1. PD/Pathogenic-10

      CasePD/Pathogenic-10: 2 weeks diagnosis

      HPOsFreeText: GAA activity 5.5 (nmol · h−1 · mg−1), Mean percentage of normal 7.8%

      GenotypingMethod: Newborn Screening Panels


      Variant1: NM_000152.4:c.271G>A (p.Asp91Asn)

      ClinVar: 4020 https://www.ncbi.nlm.nih.gov/clinvar/variation/4020/

      gnomAD: European (Non-Finnish) 0.03291, Overall 0.02049 http://gnomad.broadinstitute.org/variant/17-78078656-G-A


      Variant2: NM_000152.4:c.2161G>T (p.Glu721Ter)

      CAID: CA401370611 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.2161G%3ET

      gnomAD: Not in gnomAD


      Variant3: NM_000152.4:c.2237G>T (p.Trp746Leu)

      ClinVar: 284776 https://www.ncbi.nlm.nih.gov/clinvar/variation/284776/

      gnomAD: European (Non-Finnish) 1.244e-4, Overall 7.798e-5 http://gnomad.broadinstitute.org/variant/17-78090814-G-T


      CaseAddInfo: Patient has one pseudodeficency allele and one pathogenic allele, Nomenclature claims Variant 2 and 3 are in cis

    1. 34-year-old affected daughter

      Patient2: Female, 34 years report, Iranian, Iran

      CasePresentingHPOs: HP:0002098, HP:0003236, HP:0002910 (Respiratory distress, Increased serum CK, Increased transaminases)

      HPOsFreeText: GAA measurement from dried blood specimen at pH 3.8 was 0.13 nmol/spot * 21 h (ref 0.9-7.2) with acarbose and 0.65 nmol/spot * 21 h (ref 1.5-10) without acarbose and 3.84 nmol/spot * 21 h at pH 7.0 (ref 1.8-17.1), AST levels at 165 (ref 0-45), ALT levels at 261 (ref 5-40), CPK levels at 1212 (ref 25-200), FEV1 at 0.83, FEV1/FVC at 90.25

      CaseAddInfo: Sibling of P1

    1. The patient

      Patient1: Male, Birth onset

      CasePresentingHPOs: HP:0001644, HP:0012420, HP:0002098, HP:0001640, HP:0002375, HP:0002789, HP:0001649, HP:0030148, HP:0001252, HP:0001712, HP:0025168, HP:0009128, HP:0002878 (Dilated cardiomyopathy, Meconium stained amniotic fluid, Respiratory difficulty, Cardiomegaly, Hypokinesia, Tachypnea, Tachycardia, Heart murmur, Muscle hypotonia, Left ventricular hypertrophy, Left ventricular diastolic dysfunction, Absent/underdeveloped muscles of extremities, Respiratory failure)

      HPOsFreeText: Apgar scores were 2155, birth weight was 3,764 g, length was 50.5 cm, Mild diffuse pulmonary markings, Had a grade II ejection systolic murmur at the left upper sternal border with intermittent gallop, A cardiac catheterization with myocardial biopsy was performed on day of life 30 which revealed marked vacuolization of cardiac myocytes, Analysis of plasma GAA activity revealed a significant deficiency (4 pmoles/hr/spot, reference range 24–94), Moderately elevated urine glucose tetrasaccharide (Hex4) of 29.6 mmol/mol creatinine (reference range: <19 for age <6 months)

      NotHPOsFreeText: The ECG showed sinus rhythm with a ventricular right axis deviation without pathognomonic changes of Pompe disease, Extremities were freely moveable, Newborn screening was normal

      CaseAddInfo: Non‐consanguineous product of a term pregnancy born to a G3P2 mother, Pregnancy was complicated by limited prenatal care, cannabinoid, and amphetamine use, Family history was negative for neuromuscular diseases but significant for multiple sclerosis and seizure disorders

    1. 6

      Case#: Patient 6, gender unknown, age unknown, ethnicity unknown

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001638, HP:0003756

      (Cardiomyopathy, Skeletal myopathy)

      CaseHPOFreeText:N/A

      CaseNotHPOs: N.A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: Sequence analysis of the GAA gene was performed in a CLIA and CAP certified laboratory.

      Cross Reactive Immune reaction was negative in peripheral blood mononuclear cells (PBMCs)

      Cross Reactive Immune reaction was not available in Dried blood spots.

      Variant: NM_000152.5(GAA):c.2297A>C (p.Tyr766Ser)

      ClinVar: 420102

      CAID: CA8815680

      gnomAD: Highest population MAF= 0.00005441 (East asian)

      ParentalGenotype: N/A

      PreviouslyPublished:N/A

    1. P10

      Patient10: Female, 1.5mo at diagnosis, 2mo at ERT

      CasePresentingHPOs:

      HPOsFreeText: classic IOPD, good response to ERT, Pompe muscle pathology score = 0.2, Glycogen = 3.1 Vv(PAS + /mf)%, larger empty vacuoles = 0 Vv (LEV/mf)%,

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: homozygous, biopsy taken from  musculus vastus lateralis

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.1157_1158insA

      CAID: CA658655614, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA658655614

      gnomAD: n/a

    1. 9

      Case9: Female, 5 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421 (Epistaxis)

      CaseHPOFreeText: Hematomas at the site of injury

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: HP:0000421

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1230del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940214

      gnomAD: N/A

    2. 8

      Case8: Female, 3 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0031364 (Epistaxis, gingival bleeding, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1073del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940580

      gnomAD: N/A

    3. 7

      Case7: Male, 1.5 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0031364, HP:0000421 (Ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.2315C>G (p.Pro772Arg)

      LegacyVariant: (p.Pro741Arg)

      ClinVar: N/A

      CAiD: CA8602740

      gnomAD: MAF in the South Asian population is 0.0002613 https://gnomad.broadinstitute.org/variant/17-42453709-G-C

    4. 6

      Case6: Female, 7 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225 (Gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1374C>G (p.Ile458Met)

      LegacyVariant: (p.Ile427Met)

      ClinVar: N/A

      CAiD: CA8603157

      gnomAD: MAF in the South Asian population is 0.003658 https://gnomad.broadinstitute.org/variant/17-42458266-G-C

    5. 5

      Case5: Female, 3 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225

      (Epistaxis, gingival bleeding)

      CaseHPOFreeText: Severe epistaxis and mild gum bleeding

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.859G>C (p.Gly287Arg)

      LegacyVariant: (p.Gly256Arg)

      ClinVar: N/A

      CAiD: CA399805008

      gnomAD: N/A

    6. 4

      Case4: Female, 18 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0000132

      (Gingival bleeding, menorrhagia)

      CaseHPOFreeText: Menorrhagia only during puberty

      CaseNotHPOs: N/A

      CaseNotHPOFreeText:N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.2264G>C (p.Arg755Pro)

      LegacyVariant: (p.Arg724Pro)

      ClinVar: N/A

      CAiD: CA8602772

      gnomAD: MAF in the European (non-Finnish) population is 0.00001060 https://gnomad.broadinstitute.org/variant/17-42454380-C-G

    7. 3

      Case3: Male, 40 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0002239, HP:0002248

      (Epistaxis, GI bleeding, hematemesis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.310+1G>A (IVS2(+1)G>A)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603502

      gnomAD: MAF in the European (non-Finnish) population is 0.00001771 https://gnomad.broadinstitute.org/variant/17-42463377-C-T

    8. 2

      Case2: Male, 3 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0030137 (Prolonged bleeding following circumcision)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1652G>A (p.Arg551Gln)

      LegacyVariant: (p.Arg520Gln)

      ClinVar: N/A

      CAiD: CA8602986

      gnomAD: MAF in the South Asian population is 0.00006536 https://gnomad.broadinstitute.org/variant/17-42457470-C-T

    9. 10

      Case10: Female, 7 years old, Indian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000790 (Epistaxis, hematuria)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Diagnosis of GT was made on the basis of quantitive determination of receptor count by flow cytometric analysis of GPIIb-IIIa

      PlateletAggregation: Diagnosis of GT was made on the basis of impaired platelet aggregation (platelet aggregation was tested against ristocetin, ADP, collagen, epinephrine and arachidonic acid)

      CasePreviousTesting: Multiplex PCR by using GPIIb primers and CSGE analysis were performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.2415del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940581

      gnomAD: N/A

    1. GT7

      Case7: GT-7, German and Jugoslav, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: c.1126-72C>T heterozygous and Father: c.1126-72C>T heterozygous

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe and bleeding time is pathogenic (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGB3

      Variant: NM_000212.2:c.1030dup and an Unregistered Variant (c.1126_72C>T) (Does not show up in CAR)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA658820875 and N/A

      gnomAD: N/A

    2. GT1

      Case1: GT-1, Turkish, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: c.2374delG heterozygous and Father: c.2374delG heterozygous

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe and bleeding time is pathogenic (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2374del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940267

      gnomAD: N/A

    3. GT12

      Case12: GT-12, Caucasian, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Mother: c.2326_2331dupGAGGCC and Father: deceased

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe and bleeding time is pathogenic (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGA2B

      Variant: NM_000419.3:c.957T>A and NM_000419.3:c.2326_2331dupGAGGCC

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804780 and CA915940324

      gnomAD: N/A

    4. GT5

      Case5: GT-5, Caucasian, gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms are severe and bleeding time is pathogenic (See Table 1) Abstract mentions patients' bleeding signs include epistaxis, mucocutaneous bleeding, haematomas, petechiae, GI bleeding and menorrhagia; however, not specified per proband.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry was performed and expression is stated as pathogenic in Table 1

      PlateletAggregation: Platelet aggregation was performed and is stated as pathogenic in Table 1; however, no specific agonists mentioned

      CasePreviousTesting: All exons of ITGA2B and ITGB3 genes as well as surrounding intron regions were amplified by PCR using intronic primers as pre-viously described (12). The purified DNA fragments were then di-rectly sequenced.

      Gene: ITGA2B

      Variant: NM_000419.3:c.408G>C and NM_000419.3:c.1787T>C

      LegacyVariant: N/A

      ClinVar: 2900

      CAiD: CA500624244 and CA115846

      gnomAD: MAF in the European (non-Finnish) population 0.00006484 http://gnomad.broadinstitute.org/variant/17-42463192-C-G and MAF in European (non-Finnish) population is 0.0001325 http://gnomad.broadinstitute.org/variant/17-42457148-A-G

    1. GTa, a 37-year-old female IrishCaucasian

      Case1: (GTa) Female, 27 years old, Irish Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: No family history of bleeding

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978

      (Bruising)

      CaseHPOFreeText: Excessive bleeding after a normal delivery

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Reduced expression of GPIIb/IIIa

      PlateletAggregation: Platelet aggregation to ADP, thrombin receptor activating peptide, thrombin and U46619 was less than 10% and ristocetin induced agglutination was normal

      CasePreviousTesting: Total RNA isolated from the proband's platelets was used as a template for RT PCR. Seven primer pairs were used to amplify overlapping regions of the entire GPIIIa coding sequence using cDNA template

      Gene: ITGB3

      Variant: NM_000212.2:c.655G>A (p.Val219Met)

      LegacyVariant: (p.Val193Met)

      ClinVar: N/A

      CAiD: CA8623016

      gnomAD: MAF in the South Asian population is 0.00003266 http://gnomad.broadinstitute.org/variant/17-45363666-G-A

    1. M5

      Case5: Patient M5, Female, French Gypsy, age is not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Figure 2 for pedigree

      ParentalGenotype: Unaffected parents see pedigree Fig 2

      CasePresentingHPOs: N/A

      CaseHPOFreeText: France, GT is particularly frequent in the Gypsy population, mainly represented by the Manouche tribe. Their clinical phenotype is the same as for classic type I disease, with a moderate and occasional severe bleeding syndrome

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis has shown that these patients' surface expresses <5% of normal GPIIIa and GPIIb levels (we are not given an exact value for each proband)

      PlateletAggregation: "Absent platelet aggregation" this is all the information we are given for platelet aggregation

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    2. M10

      Case10: Patient M10, Male, French Gypsy, age is not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Figure 2 for pedigree

      ParentalGenotype: Unaffected parents see pedigree Fig 2

      CasePresentingHPOs: N/A

      CaseHPOFreeText: France, GT is particularly frequent in the Gypsy population, mainly represented by the Manouche tribe. Their clinical phenotype is the same as for classic type I disease, with a moderate and occasional severe bleeding syndrome

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis has shown that these patients' surface expresses <5% of normal GPIIIa and GPIIb levels (we are not given an exact value for each proband)

      PlateletAggregation: "Absent platelet aggregation" this is all the information we are given for platelet aggregation

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    3. M1

      Case1: Patient M1, Female, French Gypsy, age is not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Figure 2 for pedigree

      ParentalGenotype: Unaffected parents see pedigree Fig 2

      CasePresentingHPOs: N/A

      CaseHPOFreeText: France, GT is particularly frequent in the Gypsy population, mainly represented by the Manouche tribe. Their clinical phenotype is the same as for classic type I disease, with a moderate and occasional severe bleeding syndrome

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis has shown that these patients' surface expresses <5% of normal GPIIIa and GPIIb levels (we are not given an exact value for each proband)

      PlateletAggregation: "Absent platelet aggregation" this is all the information we are given for platelet aggregation

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    1. 2

      Case1: 39 years old, Female, Jewish Iraqi

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients demonstrated lack of αIIbβ3 surface expression." No specifics are given on the percentage, but test was performed

      PlateletAggregation: Presented with mucocutaneous bleeding, absence of platelet aggregation in response to all physiological agonists in contrast to normal aggregation with ristocetin

      CasePreviousTesting: "Molecular analysis disclosed that patient 2 was homozygous for an out of frame mutation (c.2031–2041 del, exon 13) in ITGB3, and patient 4 was compound heterozygote for the same deletion and a large deletion of 11.2Kb del"

      Gene: ITGB3

      Variant: NM_000212.2:c.2051_2061del (c.2051_2061del)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940226

      gnomAD: N/A

    1. patient 9

      Case1: Patient 9, Female, 10 years old

      DiseaseAssertion: Glanzmann thrombasthenia III (Diagnosed at 3 months of age)

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding phenotypes are not specified per patient in this article, rather, it states: "Petechia, epistaxis, and prolonged bleeding after trauma were the most common symptoms among studied patients"

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: This patient has type III Glanzmann thrombasthenia; therefore, according to this article, this proband showed normal or near-nromal levels of the GPIIb/IIIa complex via flow cytometry.

      PlateletAggregation: Prolonged bleeding time, abnormal clot retraction, impaired platelet aggregation induced by most physiological agonists (ADP, epinephrine, and collagen) except ristocetin, mucosal bleeding, easy bruising, epistaxis, as well as normal prothrombin/acivated partial thromboplastin time, and normal platelet count. (This is among inclusion criteria for this study)

      CasePreviousTesting: To identify the underlying molecular mechanism of GPIIb/IIIa complex abnormalities among probands in this study, all the 30 exons of ITGA2B and the 15 exons of ITGB3 were analyzed using PCR–CSGE and DNA sequencing.

      Gene: ITGB3

      Variant: NM_000212.2:c.719G>A (p.Arg240Gln)

      LegacyVariant: N/A

      ClinVar: 13553

      CAiD: CA123224

      gnomAD: N/A

    2. patient 3

      Case3: Patient 3, Female, 27 years old

      DiseaseAssertion: Glanzmann thrombasthenia type I (Diagnosed at 10 years old)

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding phenotypes are not specified per patient in this article, rather, it states: "Petechia, epistaxis, and prolonged bleeding after trauma were the most common symptoms among studied patients"

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: This patient has type 1 Glanzmann thrombasthenia; therefore, according to this article, this proband had between 0-5% of normal levels of surface GPIIb/IIIa expression.

      PlateletAggregation: Prolonged bleeding time, abnormal clot retraction, impaired platelet aggregation induced by most physiological agonists (ADP, epinephrine, and collagen) except ristocetin, mucosal bleeding, easy bruising, epistaxis, as well as normal prothrombin/activated partial thromboplastin time, and normal platelet count. (This is among inclusion criteria for this study)

      CasePreviousTesting: To identify the underlying molecular mechanism of GPIIb/IIIa complex abnormalities among probands in this study, all the 30 exons of ITGA2B and the 15 exons of ITGB3 were analyzed using PCR–CSGE and DNA sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.113del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940264

      gnomAD: N/A

    1. Supplementary Table S1 & S2 Proband and Variant Information:

      Case62: GT65, Female, 31 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000132, HP:0000790, HP:0002239, HP:0006298

      (Epistaxis, gingival bleeding, menorrhagia, hematuria, GI bleeding, bleeding after dental procedure)

      CaseHPOFreeText: Tonsil bleeding, muscle hematomas

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.574+1G>A and NM_000419.3:c.1946+3G>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805691 and CA626121071

      gnomAD: MAF in the European (non-Finnish) population is 0.00001235 https://gnomad.broadinstitute.org/variant/17-42462918-C-T and MAF in the African population is 0.000 https://gnomad.broadinstitute.org/variant/17-42456008-C-A

    2. Supplementary Table S1 & S2 Proband and Variant Information:

      Case13: GT14, Female, 10, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000979 and HP:0006298

      (Purpura, prolonged bleeding after dental extraction)

      CaseHPOFreeText: Moderate cutaneous bleeding from birth

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% variant expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.423G>T (p.Trp141Cys) and NM_000419.3:c.2902del (p.Tyr968Metfs*163)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399806022 and CA915940332

      gnomAD: N/A

    3. Supplementary Table S1 & S2 Proband and Variant Information:

      Case51: GT51, Male, 29 years old, French/African

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421 (Epistaxis)

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.861del (p.Arg287Serfs * 34) and NM_000212.2:c.1456del (p.Cys486Alafs * 183)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940375 and CA915940376

      gnomAD: N/A

    4. Supplementary Table S1 & S2 Proband and Variant Information:

      Case58: GT60, Male, 54 years old, French/Italian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000978, HP:0002239, HP:0000225

      (Epistaxis, easy bruising, GI bleeding, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.1801T>C (p.Cys601Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623361

      gnomAD: MAF in the European (non-Finnish) population is 0.00001758 https://gnomad.broadinstitute.org/variant/17-45376784-T-C

    5. Supplementary Table S1 & S2 Proband and Variant Information:

      Case65: GT68, Male, 62 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Occasional spontaneous bleeding and frequency decreased with age

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1413C>G (p.Tyr471Ter) and "LR deletion" which is the only specification we are given

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290950376

      gnomAD: MAF in the European (non-Finnish) population is 0.000008791 https://gnomad.broadinstitute.org/variant/17-42457994-G-C

    6. Supplementary Table S1 & S2 Proband and Variant Information:

      Case22: GT25, Male, 81, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0002239

      Gastrointestinal bleeding

      CaseHPOFreeText: Life-long bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1413C>G (p.Tyr471Ter) and NM_000419.3:c.1882C>T (p.Arg628Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290950376 and CA399801310

      gnomAD: MAF in the European (non-Finnish) population 0.000008791 http://gnomad.broadinstitute.org/variant/17-42457994-G-C and MAF in Latino population is 0.00003983 http://gnomad.broadinstitute.org/variant/17-42456075-G-A

    1. GT3

      Case3: GT-3, Male, Catalan, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sisters (GT-1) and (GT-2)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421

      (Epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Standard glycoprotein analysis confirmed the absence of αIIbβ3 in their platelets but while western blotting failed to reveal αIIb, residual β3 was at about 10% of usual levels and of normal migration (illustrated for GT1 in supplemental Figure 1).

      PlateletAggregation: Platelets of all 3 patients failed to aggregate in response to a range of physiologic agonists but were agglutinated by ristocetin. Clot retraction was also defective.

      CasePreviousTesting: Screened ITGA2B and ITGB3 genes of all three probands. Direct sequencing of all coding regions and splice sites of ITGA2B (30 exons) showed mutation.

      Gene: ITGA2B

      Variant: NM_000419.3:c.131G>T and NM_000419.3:c.1440-13_1440-1del

      LegacyVariant: (p.Gly13Val)

      ClinVar: N/A

      CAiD: CA399806881 and CA913184940

      gnomAD: N/A

    2. GT2

      Case2: GT-2, Female, Catalan, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister (GT-1) and brother (GT-3)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0011891

      (Post-partum hemorrhage)

      CaseHPOFreeText: N/A

      CaseNotHPOs:

      CaseNotHPOsFreeText:

      ProteinExpression: Standard glycoprotein analysis confirmed the absence of αIIbβ3 in their platelets but while western blotting failed to reveal αIIb, residual β3 was at about 10% of usual levels and of normal migration (illustrated for GT1 in supplemental Figure 1).

      PlateletAggregation: Platelets of all 3 patients failed to aggregate in response to a range of physiologic agonists but were agglutinated by ristocetin. Clot retraction was also defective.

      CasePreviousTesting: Screened ITGA2B and ITGB3 genes of all three probands. Direct sequencing of all coding regions and splice sites of ITGA2B (30 exons) showed mutation.

      Gene: ITGA2B

      Variant: NM_000419.3:c.131G>T and NM_000419.3:c.1440-13_1440-1del

      LegacyVariant: (p.Gly13Val)

      ClinVar: N/A

      CAiD: CA399806881 and CA913184940

      gnomAD: N/A

    1. Supplementary Tables 1 and 2 combined information:

      Case8: GT8, Male, 9 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421

      (Bruising, purpura, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp) and NM_000419.3:c.2236G>T (p.Glu746Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802348 (p.Arg551Trp) and CA399798321 (p.Glu746Ter)

      gnomAD: N/A

    2. Supplementary Tables 1 and 2 combined information:

      Case38: GT38, Female, 23 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000132

      (Bruising, purpura, ecchymosis, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B and ITGB3

      Variant: NM_000419.3:c.2613del in ITGA2B (p.Leu872Cysfs*38) and NM_000212.2:c.1646G>C in ITGB3 (p.Cys549Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940594 (p.Leu872Cysfs*38) and CA400030198 (p.Cys549Ser)

      gnomAD: MAF of (p.Cys549Ser) in the East Asian population: 0.00005453 https://gnomad.broadinstitute.org/variant/17-45369890-G-C

    3. Supplementary Tables 1 and 2 combined information:

      Case33: GT33, Female, 12 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421

      (Bruising, purpura, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed a small response to ADP, no response to collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGB3

      Variant: NM_000212.2:c.719G>A (p.Arg240Gln)

      LegacyVariant: N/A

      ClinVar: 13553

      CAiD: CA123224

      gnomAD: N/A

    4. Supplementary Tables 1 and 2 combined information:

      Case31: GT31, Female, 13 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421, HP:0000225

      (Bruising, purpura, ecchymosis, epistaxis, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B and ITGB3

      Variant: NM_000419.3:c.1022C>T (p.Ala341Val) in ITGA2B and NM_000212.2:c.412G>A (p.Val138Met) in ITGB3

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804629 (p.Ala341Val) and CA400021826 (p.Val139Met)

      gnomAD: N/A

    5. Supplementary Tables 1 and 2 combined information:

      Case23: GT23, Female, 11 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421, HP:0000225, HP:0000132

      (Bruising, purpura, ecchymosis, epistaxis, gingival bleeding, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed a small response to ADP, no response to collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGB3

      Variant: NM_000212.2:c.1980C>A (p.Tyr660Ter) and NM_000212.2:c.2147G>T (p.Gly716Val)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400032983 (p.Tyr660Ter) and CA400033923 (p.Gly716Val)

      gnomAD: N/A

    6. Supplementary Tables 1 and 2 combined information:

      Case40: GT40, Male, 5 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421

      (Bruising, purpura, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter) and NM_000419.3:c.962G>T (p.Gly321Val)

      LegacyVariant: N/A

      ClinVar: 2892 (p.Arg584Ter)

      CAiD: CA115834 (p.Arg584Ter) and CA399804765 (p.Gly321Val)

      gnomAD: MAF for p.Arg584Ter in East Asian population 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

    7. Supplementary Tables 1 and 2 combined information:

      Case3: GT3, Female, 12 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421, HP:0000225

      (Bruising, purpura, ecchymosis, epistaxis, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3: c.1750C>T (p.Arg584Ter)

      LegacyVariant: N/A

      ClinVar: 2892

      CAiD: CA115834

      gnomAD: MAF in East Asian population: 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

    8. Supplementary Tables 1 and 2 combined information:

      Case6: GT6, Male, 7 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421

      (Bruising, purpura, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed 10-20% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed a small amount of response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.812C>G (p.Ala271Gly) and NM_000419.3:c.2172G>A (p.Met724Gln)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805123 (p.Ala271Gly) and CA399798895 (p.Met724Gln)

      gnomAD: N/A

    1. GT31

      Case30: (GT31) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.887_901del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA626379036

      gnomAD MAF in the South Asian population is 0.00003266 https://gnomad.broadinstitute.org/variant/17-45364541-AATGACGGGCAGTGTC-A

    2. GT12

      Case6: (GT12) Gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.641T>C (p.Leu214Pro)

      LegacyVariant: N/A

      ClinVar: 2901

      CAiD: CA115848

      gnomAD N/A

    3. GT20

      Case26: (GT20) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Brother is homozygous for the mutation and the second brother is heterozygous

      ParentalGenotype: Mother and father are heterozygous for the mutation

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1424_1427dup

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603099

      gnomAD MAF in the South Asian population is 0.0001960 https://gnomad.broadinstitute.org/variant/17-42457979-C-CACCT

    4. GT14

      Case35: (GT14) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene:

      Variant: NM_000419.3:c.188+8del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603523

      gnomAD MAF in the South Asian population is 0.0002613 https://gnomad.broadinstitute.org/variant/17-42466645-AC-A

    1. GT-20b

      Case18: (GT-20) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands GT15-GT19 are related to GT-20 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not available on bleeding phenotype/severity (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.727G>C (p.Asp243His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023600

      gnomAD: N/A

    2. GT-19b

      Case17: (GT-19) Male, carrier status, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands GT15-GT20 are related to GT-19 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not available on bleeding phenotype/severity (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.727G>C (p.Asp243His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023600

      gnomAD: N/A

    3. GT-72c

      Case53: (GT-72) Gender, age, or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not given (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.662C>T (p.Thr221Met)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623017

      gnomAD: MAF in European Finnish population 0.0001386 http://gnomad.broadinstitute.org/variant/17-45363673-C-T

    4. GT-56

      Case45: (GT-56) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Moderate (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.985G>T (p.Val329Phe)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804719

      gnomAD: N/A

    5. GT-16

      Case14: (GT-16) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands GT15-GT20 are related to GT-16 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Severe (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.727G>C (p.Asp243His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023600

      gnomAD: N/A

    6. GT-46b

      Case36: (GT-46) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT45-GT48 are related

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not available (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1879-2A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290949031

      gnomAD: N/A

    7. GT-52

      Case42: (GT-52) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT49-GT52 are related

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Moderate (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.2113del (p.Leu705Cysfs*4)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623443

      gnomAD: MAF in East Asian population: 0.0001087 http://gnomad.broadinstitute.org/variant/17-45380183-TC-T

    8. GT-51

      Case41: (GT-51) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT49-GT52 are related

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not available (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.2113del (p.Leu705Cysfs*4)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623443

      gnomAD: MAF in East Asian population: 0.0001087 http://gnomad.broadinstitute.org/variant/17-45380183-TC-T

    9. GT-13b

      Case11: (GT-13) Male, carrier, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands GT11 -GT14 are related to GT-13 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Not available (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.727G>C (p.Asp243His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023600

      gnomAD: N/A

    1. Supplementary Table S1:

      Case26: GT30, "USA"-what the supp table states, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.777+1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623036

      gnomAD: MAF in the Latino population is 0.0006774 https://gnomad.broadinstitute.org/variant/17-45363789-G-A

    2. Supplementary Table S1:

      Case59: GT69, French, age and gender are not specified here

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.1878G>C (p.Gln626His/ p.Asp585_Gln626del)

      LegacyVariant: N/A

      ClinVar: 2903

      CAiD: CA115852

      gnomAD: N/A

    3. Supplementary Table S1:

      Case14: GT15, French, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.2095-19T>A and NM_000419.3:c.2770C>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940312 and CA399792054

      gnomAD: N/A

    4. Supplementary Table S1:

      Case37: GT43a, Morrocco, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.614+1G>T and NM_000212.2:c.683G>A (p.Arg228His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023344 and CA8623025

      gnomAD: MAF in the African population is 0.00008012 https://gnomad.broadinstitute.org/variant/17-45363694-G-A

    5. Supplementary Table S1:

      Case35: GT41a, Canadian/Chinese, gender and age not specified here

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.91del (p.Ala31ProfsTer2) and NM_000419.3:c.2915dup (p.Leu973AlafsTer63)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913203486 and CA8602531

      gnomAD: MAF in the East Asian population is 0.0001088 https://gnomad.broadinstitute.org/variant/17-42452054-C-CG for the variant (p.Leu973Alafs*63)

    6. Supplementary Table S1:

      Case1: GT1, French/African, Gender or age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.1913+1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400032825

      gnomAD: N/A

    7. Supplementary Table S1:

      Case11: GT12, French, age and gender not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.565C>T (p.Pro189Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224669

      gnomAD: MAF in the European (non-Finnish) population is 0.00002638 https://gnomad.broadinstitute.org/variant/17-45362012-C-T

    8. Supplementary Table S1:

      Case31: GT36a, Spain, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.131G>T (p.Gly44Val) and NM_000419.3:c.1440-13_1440-1del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399806881 and CA913184940

      gnomAD: N/A

    9. Supplementary Table S1:

      Case17: GT20, French, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: M_000419.3:c.2800G>T (p.Val934Phe)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290946484

      gnomAD: N/A

    10. Supplementary Table S1:

      Case39: GT45, French, age and gender not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.551_626del (p.Arg184_Gln208del) and the other variant is noted as "LR deletion" and that is all the information we are given so I will note it as an Unknown Variant

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940373

      gnomAD: N/A

    1. GT2

      Case#: GT2 male, 7 years old

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: (found in appendix) HP:0000967, HP:0000979, HP:0031364, HP:0000978, HP:0002239

      ExpressionEvidence: Flow Cytometry of platelet αIIbβ3: 0%CD41, 0% CD61

      FamilyInfo: Positive consanguinity

      GenotypingMethod: Sanger DNA sequencing to identify causative mutations in each case

      ClinVar: 1691476

      CAID: CA400030171

      Variant: NM_000212.3:c.1641C>G

      GnomAD: Not Found

    1. Case25: Patient CD, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000212.2:c.1801T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623361

      gnomAD: MAF in the European non Finnish population is 0.00001758 https://gnomad.broadinstitute.org/variant/17-45376784-T-C

    2. Case5: Patient DRP, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: This variant has a typo in the paper the real variant is this: NM_000419.3:c.800 G>A and NM_000419.3:c.2930del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805147 and CA915940386

      gnomAD: N/A

    3. Case20: Patient LPR, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGB3

      Variant: NM_000212.2:c.355C>T and NM_000212.2:c.355C>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622924 and CA8623361

      gnomAD: MAF in the South Asian population is 0.0001307 https://gnomad.broadinstitute.org/variant/17-45360909-C-T and MAF in the European non Finnish pop is 0.00001758 https://gnomad.broadinstitute.org/variant/17-45376784-T-C

    4. Case24: Patient CI, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000212.2:c.1801T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623361

      gnomAD: MAF in the European non Finnish population is 0.00001758 https://gnomad.broadinstitute.org/variant/17-45376784-T-C

    5. Case9: Patient MR, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1214T>C (p.Ile374Thr)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290950815

      gnomAD: N/A

    1. 1.

      Case1: Male, now deceased

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0002239

      (Gastrointestinal bleeding)

      CaseHPOFreeText: Severe bleeding when young

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific at all

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1413C>G (p.Tyr471Ter) Codon change confirmed from PMID: 20492470 and NM_000419.3:c.1882C>T (p.Arg628Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290950376 and CA399801310

      gnomAD: MAF in European non Finnish population 0.000008791 http://gnomad.broadinstitute.org/variant/17-42457994-G-C and MAF in Latino population 0.00003983 http://gnomad.broadinstitute.org/variant/17-42456075-G-A

    2. 22.

      Case22: Female, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGB3

      Variant: NM_000212.2:c.166-2A>G (IVS2-2A>G)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224483

      gnomAD: N/A

    3. 21

      Case21: Male, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mild bleeding tendency (See Table 1 for Clinical and Biological data for selected genotyped patients

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2421G>A (p.Trp807Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399796017

      gnomAD: N/A

    4. 20.

      Case20: Female, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Moderate bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.889G>A (p.Gly296Arg) **authors say (Gly297Arg) but ensembl shows Gly296Arg

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603304

      gnomAD: MAF in the South Asian population is 0.0003267https://gnomad.broadinstitute.org/variant/17-42461681-C-T

    5. 13.

      Case13: Female, African, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1357C>T (p.Arg453Ter)

      LegacyVariant: N/A

      ClinVar: 631773

      CAiD: CA399803529

      gnomAD: N/A

    1. MU

      Case3: Patient MU, gender age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.641T>C (p.Leu214Pro)

      LegacyVariant: N/A

      ClinVar: 2901

      CAiD: CA115848

      gnomAD: N/A

    2. LH

      Case17: Patient LH, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Child is patient LN, significant other is patient LB

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.3062T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399787956

      gnomAD: N/A

    1. A 3-year-old girl

      Case1: Female, 3 year old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: An analysis of family members indicated that the Gln517Stop and Arg553Stop mutations were located on different alleles and inherited from the patient’s mother and father, respectively

      CasePresentingHPOs: HP:0004406, HP:0002248, HP:0000978, HP:0000225

      (Recurrent epistaxis, hematemesis, easy bruising, gingival bleeding)

      CaseHPOFreeText: Petechial hemorrhages

      CaseNotHPOs: HP:0001945, HP:0002014, HP:0005261

      Fever, diarreah, hemarthrosis

      CaseNotHPOsFreeText: N/A

      ProteinExpression: A flow cytometry evaluation revealed marked reduction in glycoprotein IIb/IIIa (See Table 1 for Patient's Lab results)

      PlateletAggregation: Patients platelets did not aggregate in response to ADP, epinephrine, arachidonic acid, or collagen but platelets had normal ristocetin induced aggregation

      CasePreviousTesting: Molecular genetic analysis of ITGA2B was performed which revealed mutations

      Gene: ITGA2B

      Variant: NM_000419.3:c.1642C>T (p.Gln548Ter) and NM_000419.3:c.1750C>T (Arg584Ter)

      LegacyVariant: Gln517Ter and Arg553Ter

      ClinVar: 2892

      CAiD: CA399802364 and CA115834

      gnomAD: MAF in the East Asian population is 0.0002176

    1. 11

      Case9: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 mentions family history available for this proband.

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: HP:0030402, HP:0005542

      (Abnormal platelet aggregation, prolonged clotting time)

      CaseHPOFreeText: Bleeding time greater than 20 minutes and hematocrit of 38.1%.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.286T>A (p.Cys96Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603504

      gnomAD: N/A

    2. 5

      Case5: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The identified variants were heterozygote in parents.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.538G>A (p.Gly180Arg) and NM_000212.2:c.155G>T (p.Cys52Phe)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622972 (p.Gly180Arg) CA8622859 (p.Cys52Phe)

      gnomAD: "Other" population (p.Gly180Arg) MAF is 0.0001630 https://gnomad.broadinstitute.org/variant/17-45361985-G-A and South Asian population p.Cys52Phe) MAF is 0.00003266.

    1. M9

      Case17: (M9) Female, 69 years old, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Failed to express alphaIIbbeta3 on the surface of their platelets

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    2. GT2

      Case2: (GT2) Male, 76 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: <5% surface expression levels of αIIbβ3

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGB3

      Variant: NM_000212.2:c.1260G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623200

      gnomAD MAF in the African population is 0.00004005 https://gnomad.broadinstitute.org/variant/17-45368454-G-A

    3. M16

      Case24: (M16) Male, 52 years old, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Failed to express alphaIIbbeta3 on the surface of their platelets

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    4. GT6

      Case6: (GT6), Male, 82 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: 40-55% surface expression levels of αIIbβ3

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGB3

      Variant: NM_000212.2:c.665T>C (p.Leu222Pro) and NM_000212.2:c.1871G>A (p.Cys592Tyr)

      LegacyVariant: (p.Leu196Pro) and (p.Cys624Tyr) (The paper gives legacy and current nomenclature)

      ClinVar: N/A

      CAiD: CA291224887 and CA400032726

      gnomAD MAF in the European (non-Finnish) population is 0.00006482 https://gnomad.broadinstitute.org/variant/17-45363676-T-C

    5. M1

      Case9: (M1) Male, 9 years old, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Failed to express alphaIIbbeta3 on the surface of their platelets

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    1. PDJ

      Case28: Patient PDJ

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.709_710del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623029

      gnomAD: MAF in the European non Finnish population is 0.00001796 https://gnomad.broadinstitute.org/variant/17-45363717-CAG-C

      PreviouslyPublished: Reference 45

    2. NR

      Case19: Patient NR (found in the GT database as well) gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: Menorrhagia HP:0000132

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A Undetectable

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.2941C>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399790399

      gnomAD: N/A

      PreviouslyPublished: Reference numbers 32,22 in this article

    3. 17

      Case17: Patient MO (patient found in the GT database as well) gender and age are not specified here

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000132 (Bruising, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: N/A

      ClinVar: 2892

      CAiD: CA115834

      gnomAD: MAF in the East Asian population is 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

      PreviouslyPublished: Reference numbers 29 and 30 in this article

    4. LeM

      Case10: Patient LeM (found in the GT database) gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000979, HP:0000967 (Purpura/petechiae)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: <5% of normal expression

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1366_1371del

      LegacyVariant: N/A

      ClinVar: 2898

      CAiD: CA8603160

      gnomAD: MAF in the European (non-Finnish) population is 0.000008791 https://gnomad.broadinstitute.org/variant/17-42458268-TGTCTAC-T

      PreviouslyPublished: Reference number 21 in this article

    5. CG

      Case20: Patient CG (Found in GT database) also gender and age are not specified for this patient

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: Gingival bleeding and menorrhagia HP:0000225, HP:0000132

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: About 5% of normal GPIIIa and GPIIb surface expression

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1787T>C and M_000419.3:c.3060+2T>C

      LegacyVariant: N/A

      ClinVar: 2900

      CAiD: CA115846 and CA290944108

      gnomAD: MAF in the European (non-Finnish) population is 0.0001325 https://gnomad.broadinstitute.org/variant/17-42457148-A-G and MAF in the European (non-Finnish) population is 0.00003876 https://gnomad.broadinstitute.org/variant/17-42451720-A-G

      PreviouslyPublished: References 34 and 35 in this article

    6. 4LW

      Case4: Patient LW (found in GT database)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000421, HP:0006298

      (Bruising, Epistaxis, Prolonged bleeding after tooth extraction)

      CaseHPOFreeText: Blood transfusions were needed

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: 12% of normal GPIIIa and GPIIb surface expression

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.641T>C (p.Lue214Pro)

      LegacyVariant: (p.Leu183Pro)

      ClinVar: 2901

      CAiD: CA115848

      gnomAD: N/A

      PreviouslyPublished: References 14 and 15

    1. proband‐III2

      Case3: Male, Israeli-Arab, (age is either 10 or 14)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 1C for pedigree

      ParentalGenotype: See Fig 1C for pedigree

      CasePresentingHPOs: HP:0000421, HP:0031364, HP:0000967

      (Severe epistaxis, ecchymosis, petechiae)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: No surface expression of αIIbβ3 was found in patients’ platelets (See Fig 3)

      PlateletAggregation: Absent platelet aggregation in response to ADP, epinephrine, collagen and normal ristocetin-induced platelet agglutination

      CasePreviousTesting: DNA fragments containing exons and flanking intronic regions of the aIIb and B3 genes were amplified by PCR using primers

      Gene: ITGA2B

      Variant: NM_000419.3:c.97A>G (p.Asn2Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399806951

      gnomAD: N/A

    1. CC

      Case9: Patient CC

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: αIIbβ3 expression

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.666C>A (p.Phe222Leu)

      LegacyVariant: (p.Phe191Leu)

      ClinVar: N/A

      CAiD: CA399805465

      gnomAD: N/A

    2. FO

      Case7: Patient FO

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.2153dup and NM_000419.3:c.1234G>A (p.Gly412Arg)

      LegacyVariant: (p.Gly381Arg)

      ClinVar: 381748

      CAiD: CA913189170 and CA8603182

      gnomAD MAF in the Latino population is 0.0001453 https://gnomad.broadinstitute.org/variant/17-42458406-C-T

    3. DC

      Case5: Patient DC

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs:

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    4. StopMB

      Case14: Patient MB

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: The amplification of DNA fragments using PCR and their electrophoretic migration through a denaturing gradient was used to scan the entire coding region, splice site junctions and promoter regions of the GPIIb and GPIIIa genes for all 20 patients in this study

      Gene: ITGA2B

      Variant: NM_000419.3:c.1211-78A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940720

      gnomAD: N/A

    1. I

      Case9: Patient ID I, Female, 3 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Related to Patient's J and K (See Table 1)

      ParentalGenotype: N/A (Parents are consangenous)

      CasePresentingHPOs: HP:0000967, HP:0000979, HP:0000978, HP:0004406

      (Petechiae, purpura, easy bruising, recurrent epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: HP:0000225, HP:0002239, HP:0002239, HP:0000790, HP:0005261, HP:0002248

      (Gingival bleeding, GI bleeding, intracranial hemorrhage, hematuria, hemarthrosis, hematemesis)

      CaseNotHPOsFreeText: Hemorrhage after dnetal, hemorrhage after trauma, ear bleeding, hematoma

      ProteinExpression: N/A

      PlateletAggregation: Defective response to ADP, adrenaline, collagen, arachidonic acid, and normal response to ristocetin

      CasePreviousTesting: Exon PCR was used to amplify coding regions of the ITGA2B and ITGB3 genes. PCR products were purified and Sanger sequenced. Segregation using parental samples was undertaken when available.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1652G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602986

      gnomAD: MAF in South Asian population is 0.00006536 http://gnomad.broadinstitute.org/variant/17-42457470-C-T

      PreviouslyPublished: PMID: 19172520

    1. GT 04

      Case15: GT04, Female, India, age of onset is 11 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: Menorrhagia HP:0000132

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.262C>T (p.Arg88Ter) and NM_000212.2:c.356G>A (p.Arg119Gln)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400020703 and CA8622925

      gnomAD: MAF in the Other population is 0.0001385 https://gnomad.broadinstitute.org/variant/17-45360816-C-T and MAF in the African population is 0.0002470 https://gnomad.broadinstitute.org/variant/17-45360910-G-A

    2. GT 07

      Case16: GT07, Male, India, age of onset is 3 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.153del (p.Trp51CysfsTer5)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940728

      gnomAD: N/A

    3. GT 55

      Case34: GT55, Male, India, age of onset is 21 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.921C>A (p.Tyr307Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400025209

      gnomAD: N/A

    4. GT 24

      Case6: GT24, Male, India, age of onset is 10 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.2898_2902dup

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940725

      gnomAD: N/A

    5. GT 40

      Case29: GT40, Female, India, age of onset is 6 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.428T>G (p.Leu143Trp)

      LegacyVariant: N/A

      ClinVar: 13567

      CAiD: CA123252

      gnomAD: MAF in the Other population is 0.0001629 https://gnomad.broadinstitute.org/variant/17-45361875-T-G)

    6. GT 09

      Case18: GT09, Female, India, age of onset is 21 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.428T>G (p.Leu143Trp) and NM_000212.2:c.1261G>A (p.Val422Met)

      LegacyVariant: N/A

      ClinVar: 13567

      CAiD: CA123252 and CA400028437

      gnomAD: MAF in the Other population is 0.0001629 https://gnomad.broadinstitute.org/variant/17-45361875-T-G

    1. The probands are two brothers, 18

      Case1: Male, 18 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Figure 4 for family pedigree of patients carrying the 288delC mutation in GPIIb

      ParentalGenotype: Heterozygous for variant

      CasePresentingHPOs: HP:0000978 (Bruising)

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis shown in Fig 1

      PlateletAggregation: Platelets failed to aggregate either spontaneously or in response to ADP, adrenaline, collagen or arachidonic acid, but they showed agglutination in the presence of ristocetin

      CasePreviousTesting: ITGA2B and ITGB3 both were sequenced

      Gene: ITGA2B

      Variant: NM_000419.3:c.291del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940464

      gnomAD: N/A

    1. Table 3 Molecular Diagnosis of Patients with Glanzmann Thrombasthenia:

      Case5: GT-5, age, gender, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Segregation analysis confirmed in presence of heterozygous mutations in this proband.

      ParentalGenotype: Although segregation analysis confirmed, we do not know which variant in particular came from mom or dad.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients presented with a variable bleeding diathesis; most patients had epistaxis (54%), cutaneous bleeding (58%), and menorrhagia (100% of women) while other common symptoms (oral cavity, GI, following dental extraction of mild injuries, postpartum, or hematomas) were in general milder. There is no specific phenotypes attached to probands in this paper.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that αIIbβ3 expression was less than 5%

      PlateletAggregation: There was severely impaired aggregation in response to all physiological agonists, and ristocetin induced platelet agglutination was normal or reduced to some extent.

      CasePreviousTesting: Total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Then, using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing. Every mutation found in cDNA was confirmed in DNA samples.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2637del (c.2637delC) and

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940297

      gnomAD: N/A

    2. Table 3 Molecular Diagnosis of Patients with Glanzmann Thrombasthenia:

      Case3: GT-3, age, gender, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type II

      FamilyInfo: Segregation analysis confirmed in presence of heterozygous mutations in this proband.

      ParentalGenotype: Although segregation analysis confirmed, we do not know which variant in particular came from mom or dad.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients presented with a variable bleeding diathesis; most patients had epistaxis (54%), cutaneous bleeding (58%), and menorrhagia (100% of women) while other common symptoms (oral cavity, GI, following dental extraction of mild injuries, postpartum, or hematomas) were in general milder. There is no specific phenotypes attached to probands in this paper.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that αIIbβ3 expression was between 5% and 20%.

      PlateletAggregation: There was severely impaired aggregation in response to all physiological agonists, and ristocetin induced platelet agglutination was normal or reduced to some extent.

      CasePreviousTesting: Total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Then, using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing. Every mutation found in cDNA was confirmed in DNA samples.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Arg705Cys)

      LegacyVariant: (p.Cys674Arg)

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in European non-Finnish population is 0.000008792

    1. 56-year-old Algerian woman

      Case1: Female, 56 years old, Algerian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0004406, HP:0000132

      (Recurrent epistaxis, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: No platelet αIIbβ3 expression (mentioned briefly in abstract)

      PlateletAggregation: The patient shows all the typical signs of GT with no platelet aggregation in response to physiologic agonists and an absence of clot retraction. No mention of ristocetin

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1063G>A (p.Glu355Lys)

      LegacyVariant: p.Glu324Lys

      ClinVar: 2899

      CAiD: CA115844

      gnomAD: MAF in European (non-Finnish population 0.00001978 http://gnomad.broadinstitute.org/variant/17-42461008-C-T

      PreviouslyPublished: Proband 9 in PMID: 2180491

    1. 6CabGT-6

      Case6: (Proband, CabGT-6), Male, age not specified, Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed <5% surface expression of GPIIIa and GPIIb

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.1413C>G (p.Tyr471Ter) and NM_000419.3:c.2800G>T (p.Val934Phe)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290950376 (p.Tyr471Ter) and CA290946484 (p.Val934Phe)

      gnomAD MAF in the European (non-Finnish) population is 0.000008791 https://gnomad.broadinstitute.org/variant/17-42457994-G-C

    2. 15CabGT-15

      Case15: (Proband CabGT-15)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: N/A

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.2800G>T (p.Val934Phe)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290946484

      gnomAD N/A

    3. 21CabGT-21

      Case21: (ProbandGT-21) Male, age not specified, Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed <5% GPIIIa and GPIIIb surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGB3

      Variant: NM_000212.2:c.191G>A (p.Cys64Tyr) the second mutation was not identified

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224490

      gnomAD N/A

    4. 12

      Case12: (Proband CabGT-12), Female, age not specified, Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed 19% GPIIb and 40% GPIIIa surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg) and NM_000419.3:c.3060+2T>C (p.Val982_Lys1020del)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602816 and CA290944108

      gnomAD MAF in the European (non-Finnish) population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G and MAF in the European non Finnish population for (p.Val982_Lys1020del) is 0.00003876 https://gnomad.broadinstitute.org/variant/17-42451720-A-G

    1. 2

      Case2: Female, 67 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A per Table 1

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Prolonged ivy bleeding times, bleeding diathesis since early childhood

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Surface expression of αIIbβ3 was analyzed by flow cytometry which was < 5% of normal

      PlateletAggregation: Aggregation in response to ADP, epinephrine and collagen was absent but normal in response to ristocetin

      CasePreviousTesting: Nucleotide sequences of the αIIb and β3 coding regions were determined by direct sequencing of RT-PCR products from platelet RNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1063G>A (p.Glu355Lys)

      LegacyVariant: (p.Glu324Lys)

      ClinVar: 2899

      CAiD: CA115844

      gnomAD: MAF in the European (non-Finnish) population is 0.00001978 https://gnomad.broadinstitute.org/variant/17-42461008-C-T

    2. cases 1

      Case1: Female, 25 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A per Table 1

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Prolonged ivy bleeding times, bleeding diathesis since early childhood

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Surface expression of αIIbβ3 was analyzed by flow cytometry which was < 5% of normal

      PlateletAggregation: Aggregation in response to ADP, epinephrine and collagen was absent but normal in response to ristocetin

      CasePreviousTesting: Nucleotide sequences of the αIIb and β3 coding regions were determined by direct sequencing of RT-PCR products from platelet RNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.959T>C (p.Phe320Ser)

      LegacyVariant: (p.Phe289Ser)

      ClinVar: N/A

      CAiD: CA399804774

      gnomAD: N/A

    1. Click here for additional data file

      Case Info Found in supplementary data:

      Case#: Patient GT, Female 43 years old. Greek family.

      FamilyInfo: Two sisters, one affected.

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0003540, HP:0000967, HP:0031364, HP:0000421, HP:0000225, HP:0000978, HP:0000132

      Impaired platelet aggregation, Petechiae, Ecchymosis, Epistaxis, Gingival bleeding, bruising susceptibility, Menorrhagia,

      PlateletAgreggation: Light transmission aggregometry studies demonstrated no aggregation in response to ADP, epinephrine, collagen, and arachidonic acid, but a normal response to ristocetin.

      GenotypingMethod: Reverse transcription PCR of platelet RNA confirmed the presence of a homozygous β3 C575R mutation.

      ClinVar: NA

      PAID: PA2573320341 (almost certainly CA400032399 but no c. reported)

      Variant: NA

      GnomAD: NA

      ExpressionEvidence: Flow cytometry demonstrated normal platelet binding of an antibody to GPIb, but virtually no binding of mAb 7E3. Immunoblot analysis demonstrated the presence of <20% of normal β3, with a faint band corresponding to pro-αIIb

    1. Supplemental Table S1:

      Case12: Male, Italy, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: Moderate bleeding

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: <5% αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1742C>A (p.Ala581Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802112

      gnomAD: N/A

      PreviouslyPublished: PMID: 12083483

    1. Mother L

      Case1: Mother L

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Assessment of surface PTL expression of GPIIIa-IIb was performed

      PlateletAggregation: N/A

      CasePreviousTesting: DNA sequence analysis was performed -- direct sequence analysis of the PCR products corresponding to exon 10 was performed here

      Gene: ITGA2B

      Variant: NM_000212.2:c.1447T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400029321

      gnomAD: N/A

    1. Case 1

      Case#: 11 yo, Female

      DiseaseAssertion: GT

      FamilyInfo: No family hx. No pedigree.

      CasePresentingHPOs: (HP:0002249) Melena; (HP:0000421) Epistaxis; (HP:0000225) Gingival bleeding; (HP:0100769) Synovitis; (HP:0005261) Joint hemorrhage, right ankle; (HP:0001891) Iron deficiency anemia;

      PlateletAggregation: Prothrombin time: 11, Partial thromboplastin time: 26, Platelet function analyzer-100: >300

      CaseHPOFreeText: stable intestinal angiodysplasia

      ProteinExpression: Flow cytometry: CD41 and 61 <50%

      CasePreviousTesting: Molecular sequencing, Patients’ information was obtained from the medical record system of the Madinah Hereditary Blood Disorders Center, Maternity and Children Hospital, King Fahd Hospital, Al Madinah, Saudi Arabia.

      Gene: ITGB3

      HGVS: NM_000212.3:c.2111_2112del

      ClinVar:

      CAID: CA3062865178

      gnomAD:

    1. GT5

      Disease: Glazmann's Thrombasthenia

      Case: 48 year old female French Gypsy

      CasePresentingHPOs: HP:0001975

      (Decreased platelet glycoprotein IIb-IIIa)

      GenotypingMethod:Genotyping analysis of the HPA-1 system by high resolution melting analysis (methods not provided, cited article I don't have access too)

      ClinVar: 2895

      CAID: CA10575473

      Variant: NM_000419.5:c.1544+1G>A

      GnomAD: Not found

      ExpressionEvidence: Failed to express αIIbβ3 integrin on their platelet surface (methods not provided cited article no access too)

    1. 13

      Case2: Female, 41 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: "This mutation was confirmed in the proband and parents."

      CasePresentingHPOs: HP:0000225 (Gingival bleeding)

      CaseHPOFreeText: Site of bleeding: Skin

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: See Table 1 (information provided)

      PlateletAggregation: See Table 1 (information provided)

      CasePreviousTesting: Screened mutations in ITGA2B and ITGB3 by multiplex polymerase chain reaction (PCR) amplification (MPCR) and conformation-sensitive gel electrophoresis

      Gene: ITGA2B

      Variant: NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: N/A

      ClinVar: 2892

      CAiD: CA115834

      gnomAD: MAF in the East Asian population is 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

    1. 23

      Case23: Female, Arab, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 mentions family history available for the proband, however no specific details about family provided in paper

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000132)

      (Epistaxis, menorrhagia)

      CaseHPOFreeText: Haematuria

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.409-2_419del

      LegacyVariant: N/A

      ClinVar: 2889

      CAiD: CA10575471

      gnomAD: N/A

    1. A 62‐year‐old Egyptian male

      Case#: Male, 62, Egyptian

      DiseaseAssertion: GT with concurrent platelet CD36 deficiency (~1 in 100 million) and anti‐CD36 antibodies

      CasePresentingHPOs: HP:0000421,Epistaxis. HP:0000978, Bruising susceptibility. HP:0000225, Gingival bleeding. HP:0001903, Anemia. HP:0001934, Persistent bleeding after trauma. HP:0001058, Poor wound healing. HP:0002573, Hematochezia. HP:0005261, Joint hemorrhage.

      PlateletAggregation: See Table 1. Normal platelet count. Normal platelet size, modestly elevated mean platelet volume. Normal response to ristocetin.

      ProteinExpression: Flow cytometry. GPIb/IX Expression 108% (range: 65-124%); GPIIb/IIIa expression 0% (range:65-124%).

      Gene: ITGA2B

      Variant: c.2148dup, p.Leu717Alafs3X

      HGVS: NM_000419.5:c.2148dup

      ClinVar: 627273

      CAID: CA915940304

      gnomAD: Absent

      Variant: c.1234G>A, p.Gly412Arg

      HGVS: NM_000419.5:c.1234G>A

      ClinVar: 381748

      CAID: CA8603182

      gnomAD: 0.00003236, https://gnomad.broadinstitute.org/variant/chr17-44381038-C-T?dataset=gnomad_r4

    1.  Case 1

      Case1: Female, 9 years old, Japanese

      DiseaseAssertion: Macrothrombocytopenia

      FamilyInfo: Information given in Table 1 and Fig 2

      ParentalGenotype: Mother: ITGA2B (p.Arg422Ter heterozygous) and Father: ITGA2B (p.Gly991Cys heterozygous) See Table 1 for this information

      Sequencing of parental DNA indicated parental mutations. CasePresentingHPOs: HP:0000979, HP:0000421, HP:0000978

      (Purpura, epistaxis, bruising)

      CaseHPOFreeText: Hemorrhage after dental

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometric analysis showed that surface αIIbβ3 expression in platelets (was markedly impaired 3-11%)

      PlateletAggregation: N/A

      CasePreviousTesting: Sequence analysis of entire coding regions of exons and exon-intron boundaries of ITGA2B and ITGB3 gene of the patient revealed two novel mutations in ITGA2B.

      Gene: ITGA2B

      Variant: NM_000419.3:c.3064G>T (p.Gly1022Cys) and NM_000419.3:c.1357C>T (p.Arg453Ter)

      LegacyVariant: (p.Gly991Cys legacy nomenclature for p.Gly1022Cys) and (p.Arg422Ter legacy nomenclature for p.Arg453Ter)

      ClinVar: 631773

      CAiD: CA399787943 and CA399803529

      gnomAD: N/A

    1. Case1: Male, 61 years old, Iraqi-Jewish origin

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: His sister is the other proband in this article

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0000225, HP:0031364, HP:0002249

      (Gingival bleeding, epistaxis, ecchymosis, melena)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Surface expression GPIIb/IIIa was 9% of normal

      PlateletAggregation: Platelet aggregation in response to thrombin, collagen, ADP and epinephrine was absent, whereas ristocetin induced aggregation was normal

      CasePreviousTesting: DNA fragments containing exons and flanking intronic regions of the GPIIb gene were amplified by PCR

      Gene: ITGA2B

      Variant: NM_000419.3:c.1947-2A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399801096

      gnomAD: N/A

    1. GTP1

      Case1: GTP1, gender, age, or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Sequencing of both parental genomic DNA confirmed patient was homozygous for IVS4+1G>A mutation

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% αIIbβ3 expression, which was confirmed by western blot analysis

      PlateletAggregation: N/A

      CasePreviousTesting: Sequencing of patient genomic DNA was done on ITGA2B (no mention of ITGB3)

      Gene: ITGA2B

      Variant: NM_000419.3:c.574+1G>A (IVS4+1G>A)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805691

      gnomAD: MAF in the European non-Finnish population 0.00001235 http://gnomad.broadinstitute.org/variant/17-42462918-C-T

  2. www.researchgate.net www.researchgate.net
    1. Patient 4

      Case4: Patient 4, Female, 12 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister is Patient 3

      ParentalGenotype: N/A (Not consanguineous Caucasians, showed no increased bleeding tendency)

      CasePresentingHPOs: HP:0000967

      (Petechiae)

      CaseHPOFreeText: Hematomas, prolonged in vitro bleeding time

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis revealed that there was no surface expression of GPIIb/IIIa for Patient 4 and there was approx. 1520 of GPIIb/IIIa expression for Patient 4.

      PlateletAggregation: All patients' platelets showed severely reduced platelet aggregation after stimulation with collagen and ADP in contrast to the normal range (See Table 1). Stimulation with epinephrine and arachidonic acid also demonstrated decreased platelet aggregation. In contrast, ristocetin-induced platelet aggregation was within a normal range.

      CasePreviousTesting: Sequenced ITGA2B and ITGB3 genes from one patient of each family (Patient 2 and 3) and Patient 1 and 4 were screened for the identified mutation in the corresponding family.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1787T>C (p.Ile596Thr)

      LegacyVariant: N/A

      ClinVar: 2900

      CAiD: CA115846

      gnomAD: MAF in the European (non-Finnish) population is 0.0001325 http://gnomad.broadinstitute.org/variant/17-42457148-A-G

    1. A female patient

      Case1: Female, 20 years old, Chinese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000421,

      (Easy bruising, epistaxis)

      CaseHPOFreeText: Prolonged bleeding time (more than 20 minutes, absent clot retraction

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Decreased of surface expression of αIIb and β3 in patient's platelets

      PlateletAggregation: Absent in vitro platelet aggregation in response to ADP, epinephrine, and collagen, but relatively normal ristocetin induced platelet aggregation

      CasePreviousTesting: DNA fragments containing exons and flanking intronic regions of ITGA2B and ITGB3 genes were produced by PCR using primers. Amplified fragments were subjected to analysis by direct DNA sequencing

      Gene: ITGA2B

      Variant: NM_000419.3:c.527C>A (p.Pro157His)

      LegacyVariant: (p.Pro126His)

      ClinVar: N/A

      CAiD: CA8603447

      gnomAD: MAF in the African population is 0.00006689 http://gnomad.broadinstitute.org/variant/17-42462966-G-T

    1. The patient

      Case1: Male, 7 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See pedigree Fig 5

      ParentalGenotype: Parents heterozygous for the mutation proband has

      CasePresentingHPOs:

      (Petechia, bruising

      CaseHPOFreeText: Mucocutaneous hemorrhages

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: There was a lack of platelet surface expression of the GPIIb-IIIa complex as shown by Western blotting

      PlateletAggregation: Platelets fail to aggregate spontaneously or in response to agonists, although they agglutinate in response to ristocetin

      CasePreviousTesting: Screening of mutations in both ITGA2B and ITGB3 was carried out by single stranded conformational polymorphism (SSCP) analysis

      Gene: ITGA2B

      Variant: NM_000419.3:c.1882C>T (p.Arg628Ter)

      LegacyVariant: (p.Arg597Ter)

      ClinVar: N/A

      CAiD: CA399801310

      gnomAD: MAF in the Latino population is 0.00003983 http://gnomad.broadinstitute.org/variant/17-42456075-G-A

    1. The proband (II2) was a 7-year-old male child at the time of diagnosis.

      Case#: II2 Figure 1A, Male, 7yo

      DiseaseAssertion: Glanzmann's thrombasthenia

      **FamilyInfo: ** Figure 1A, non-consanguineous, sibling (II1) died at 5yo, sibling (II3) in good health, mother and father heterozygous carriers

      ParentalGenotype: both parents heterozygous carriers

      CasePresentingHPOs: (HP:0001933) subcutaneous bleeding, (HP:0004406) spontaneous epistaxis, (HP:0011858) coagulation factor IX decreased

      PlateletAggregation: Platelets were normal, coagulation factors normal, vWF factor normal, bone marrow normal. Platelet count via LH780 automatic blood analyzer, vWF via immunoturbidimetry, CD41(GPⅡb)/CD6l (GPⅢa) and CD42b via flow cytometry.

      CaseHPOFreeText:Hemophilia B. Mutation in the F9 gene c.8G > A of unknown clinical significance, considered non-pathogenic.

      CaseNotHPOs:

      **CaseNotHPOFreeText: **

      ProteinExpression: Flow cytometry results revealed that CD41 (GPⅡb) and CD6l (GPⅢa) were 2.05% and 0%, respectively (normal values ​​ranged from 95% to 97%), suggesting that the expression of platelet surface membrane glycoprotein GPIIb/IIIa was significantly reduced.

      CasePreviousTesting: Whole exome sequencing verified by Sanger sequencing. Whole gene synthesis, qPRC analysis, Western blotting.

      **PreviouslyPublished: **

      Gene: ITGB3

      Variant: c.1431C > T/p.Gly477 = in ITGB3 exon10 in the proband

      HGVS: NM_000212.3:c.1431C>T

      **ClinVar: ** 3242396

      **CAID: ** CA500651220

      gnomAD: Absent

    1. Case1: Female, 48 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000978, HP:0000132, HP:0006298, HP:0005261

      (Epistaxis, gingival bleeding, easy bruising, menorrhagia, bleeding after tooth extraction, hemarthrosis

      CaseHPOFreeText: Hemorrhage after surgery

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Platelet surface glycoprotein analysis by flow cytometry revealed a severe αIIbβ3 deficiency (Table 3 shows specific values)

      PlateletAggregation: There was a failure of ADP, collagen and adrenalin to induce platelet aggregation, but ristocetin-induced platelet aggregation (RIPA) was normal

      CasePreviousTesting: Integrin alphaIIb subunit gene (ITGA2B) sequencing showed that this proband was a compound heterozygote

      Gene: ITGA2B

      Variant: NM_000419.3:c.1214T>C (p.Ile405Thr) and NM_000419.3:c.1234G>A (p.Gly412Arg)

      LegacyVariant: (p.Ile374Thr) (p.Gly381Arg)

      ClinVar: 381748

      CAiD: CA290950815 (p.Ile403Thr) and CA8603182 (p.Gly412Arg)

      gnomAD: MAF in Latino population 0.0001453 http://gnomad.broadinstitute.org/variant/17-42458406-C-T

    1. P4

      Case4: P4, gender, age, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Article mentions all patients have a severe bleeding phenotype

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: αIIbβ3 expression levels were (0.6% in patient 4)

      PlateletAggregation: N/A

      CasePreviousTesting: Acknowledgements section mentions acknowledging the Genoscope team for sequencing both ITGA2B and ITGB3 genes of the GT patients in this article

      Gene: ITGA2B

      Variant: NM_000419.3:c.857T>A (p.Val268Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805011

      gnomAD: N/A

    1. A 56-year-old Japanese female

      Case1: Female, 56 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia (Diagnosed at 21 years of age)

      FamilyInfo:

      ParentalGenotype:

      CasePresentingHPOs: HP:0004406, HP:0000225

      (Recurrent epistaxis, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry demonstrated significantly decreased expression of CD41 and CD61 to less than 20% of normal levels (See Figure 2)

      PlateletAggregation: An in vitro assay revealed no platlet aggregation in response to agonists except ristocetin.

      CasePreviousTesting: DNA sequencing analysis revealed compound heterozygous mutations confirming a diagnosis of Glanzmann thrombasthenia

      Gene: ITGA2B

      Variant: NM_000419.3:c.2602-3C>G and NM_000419.3:c.641T>C (p.Leu214Pro)

      LegacyVariant: N/A

      ClinVar: 2893 and 2901

      CAiD: CA10575472 and CA115848

      gnomAD: MAF in East Asian population 0.00006523 http://gnomad.broadinstitute.org/variant/17-42453087-G-C

    1. Case1: Female, 29 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Parents were heterozygous for mutation (parents are first cousins)

      CasePresentingHPOs: HP:0001892, HP:0000421, HP:0000225, HP:0000132

      (Severe hemorrhagic diathesis, epistaxis, gingival bleeding, menorrhagia)

      CaseHPOFreeText: Patients severe hemorrhagic diathesis manifested as epistaxis

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: Amplification of reversely transcribed platelet GP IIIa mRNA by the polymerase chain reaction and subsequent sequence analysis showed a 86-bp deletion, which corresponds to exon i of the GP IIIa gene.

      Gene: ITGB3

      Variant: NM_000212.2:c.165+1G>T (No other assertion was made about the 2 other variants in this article, just this variant that is mentioned in this annotation)

      LegacyVariant: N/A

      ClinVar: 13560

      CAiD: CA400031853

      gnomAD: N/A

    1. Patient F4.II.1

      Case#: Male, 48

      Disease: Glazmann's Thrombasthenia Like Syndrome

      CasePresentingHPOs: HP:0001873, HP:0000421, HP:0031364, HP:0000225

      Thrombocytopenia, Epistaxis, Ecchymosis, Gingival bleeding

      CaseNotHPOs: NA

      FamilyInfo: Pedigree figure 1. Family history of thrombocytopenia.

      PlateletAgreggation: Decreased PLT aggregation and diminished ATP release with the agonists ADP, collagen, and AA, with normal ristocetin agglutination

      GenotypingMethod: Genetic analysis of ITGA2B and ITGB3 genes was performed by next-generation sequencing (NGS). Sanger sequencing used to confirm variants.

      ClinVar: 50232

      CAID: CA10575572

      Variant: NM_000419.5:c.3077G>A

      GnomAD: European non-Finnish 0.000008801 (1/113618)

      ExpressionEvidence: Level of expression on PLT surface determined by FCM: CD41a (GPIIb/IIIa) 49%, CD61 (GPIIIa) 44%, and CD42b (GPIb) 105%. Healthy control value range: CD41a (GPIIb/IIIa) (85-115%); CD61 (GPIIIa) (80-120%); CD42b (GPIb) (70-130%).

    1. Table 1

      Case# P4, 4yr onset, Pakistani

      CasePresentingHPOs HP:0002151, HP:0001946, HP:0001942, HP:0001987

      CasePreviousTesting negative for NAGS and CPS1 genes.

      CaseGenotypingMethod sequence analysis of coding exons, including flanking intronic regions of CA5A and CA5B, was performed.

      Variant NM_001739.1:c.555+4_555+183del180bp

      CAID CA658820661

      VariantEvidence intronic splice site

      CaseAddInfo consanguineous

    1. Table 1

      Case3b: Female, 9 d at initiation of follow up, East Indian ancestry, sibling of Case 3a (Family 1)

      HPOsFreeText: NBS C4-acylcarnitine 2.1 umol/L, Plasma C4-acylcarnitine 2.47 umol/L, urine C4-acylcarnitine 21.66 mmol/mol creatinine, Urine C4/C3 ratio 42

      NotHPOsFreeText: normal urine isobutyrylgycine ug/mg creatinine

      CaseAddInfo: unremarkable clinical condition

      Case3b (Level 2)


      CasePreviousTesting: same as group

      CaseMethod1: same as group

      CaseMethod2: same as group

      CaseGenotypingMethod: same as group


      Variant: NM_014384.2(ACAD8):c.867C>A (p.His289Gln)

      ClinVar: 5358

      CAID: CA117441

      gnomAD: not in gnomAD


      CaseAddInfo: homozygous mutations, no data for SCAD gene variants

    1. a family with EA

      FamilyKDC: Korea

      FamilyPresentingHPOs: HP:0001251, HP:0002321, HP:0002018 (Ataxia, Vertigo, Nausea)

      HPOsFreeText: N/A

      FamilyNotHPOs: N/A

      NotHPOsFreeText: N/A

      FamilyGenotypingMethod: Genomic DNA was extracted fom patient blood samples. Whole exome sequencing was performed. Sequence variants in KCNA1, CACNA1A, CACNB4 and SLC1A3 were all searched with pathogenicity-based variant filtering. The found variant was further confirmed via PCR and Sanger sequencing.

      FamilyPreviousTesting: Ataxic episodes usually provoked by stress; Responded to treatment with acetazolamide

      FamilyAddInfo: N/A

      Variant: NM_004172.5:c.1177G>A (p.Val393Ile)

      CAID: CA3235626, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA3235626

      gnomAD: 0.0002940, https://gnomad.broadinstitute.org/variant/5-36680579-G-A NOTE FREQUENCY VERY HIGH

      Affected: 2

      Segregations: 1

      AddSegregationInfo: NOTE INCONSISTENT SEGREGATIONS, Not enough info to count, Pedigree in Figure 1A